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Inflammation is a necessary biological response to injury and infections, but chronic 
activation can lead to a host of diseases. This beneficial-turned-destructive process plays a 
fundamental role in the development of cardiovascular diseases, and the vascular response 
requires communication between multiple cell types such as vascular smooth muscle cells 
(VSMC) and macrophages. A PDZ-domain scaffolding protein, Ezrin-Radixin-Moesin-Binding 
Phosphoprotein 50 (EBP50, also known as NHERF1), is expressed at low levels in normal 
vessels but is upregulated following arterial wire injury and promotes neointima formation. 
However, the mechanisms underlying these actions are not fully understood. I hypothesized that 
EBP50 functions as a central mediator of macrophage activation and the response of VSMC to 
inflammation. EBP50 expression increased in an NF-κB-dependent manner upon LPS or TNFα 
treatment macrophages and VSMC. Conversely, NF-κB activation was impaired in EBP50 
knockout (KO) VSMC and macrophages. Mechanistically, inflammatory stimuli induced the 
formation of an EBP50-PKCζ complex that promoted PKCζ membrane translocation and 
subsequent NF-κB signaling. Macrophage cytokine production (IL-1β, TNFα) and vascular 
adhesion molecule expression (ICAM-1, VCAM-1) after acute LPS or TNFα treatment were 
reduced in KO cells and mice compared to WT. Bridging the multicellular effects of EBP50,  
macrophage recruitment to lesions in the femoral artery one week after wire injury was 
significantly reduced in KO mice.  
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 The effect of myeloid cell-specific EBP50 on atherosclerosis was determined in 
Ldlr
-/-
 mice, a well-established model of diet-induced atherosclerosis. Mice were lethally 
irradiated and transplanted with bone marrow from WT or KO mice and kept on a high-
cholesterol diet for 12 weeks. A complete blood count and genotyping of hematopoietic cells 
established the successful ablation of original bone marrow and the full reconstitution of the 
donor marrow. No differences in weight, blood glucose, or cholesterol levels were observed 
between the two groups. Oil Red O staining of sections throughout the aorta revealed a 25% 
reduction in lesion area in KO bone marrow recipients compared to WT.  
 Collectively, these new findings indicate that EBP50 potentiates macrophage 
activation and the response of VSMC to inflammation. Thus, EBP50 is a key regulator of 
vascular remodeling during both acute and chronic inflammatory states. 
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1.0  INTRODUCTION 
1.1 ATHEROSCLEROSIS: AN INFLAMMATORY DISEASE 
Large arteries that are more prone to atherosclerosis consist of three major layers: the intima, 
media, and adventitia (1). As depicted in Figure 1-1, the intima is a single layer of endothelial 
cells (and vascular smooth muscle cells (VSMC) in humans) that serves as a protective barrier 
between the blood-carrying lumen and the underlying medial VSMC. A thin layer of connective 
tissue and elastin bands called the internal elastic lamina separates the intima from the media, the 
thickest segment of an artery. Medial VSMC contract or relax and thus dictate the volume of a 
vessel and its blood pressure. The outermost layer of an artery, the adventitia, is divided from the 
media by the external elastic lamina and mainly contains fibroblasts and connective tissue. A 
network of capillaries within the adventitia called the vasa vasorum supplies the vessel with 
nutrients and can additionally serve as an alternative route of entry for leukocytes.  
Dysfunction of any of these features sets off a chain of events down the path of 
cardiovascular disease (CVD). CVD includes, but is not limited to, myocardial infarction, heart 
failure, hypertension, stroke, atherosclerosis, and restenosis. Although mortality rates have 
declined since the 1970s, CVD is still responsible for a sizeable 32.3% of deaths every year in 
the United States, amounting to one death every 40 seconds (2). While much information about 
the mechanisms of CVD has been gathered, it is clear that there is still much more to learn.  
It is increasingly evident that atherosclerosis is an inflammatory disease (3-6). Any 
alteration in the integrity of the endothelium triggers a coordinated response of multiple cell 
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types. Dysfunctional endothelium recruits monocytes and allows for their transmigration through 
the VSMC layer (Figure 1-1). Monocytes further mature into macrophages and engulf 
cholesterol, forming foam cells and eventually contributing to the development of the necrotic 
core. In response to the heightened inflammatory environment, VSMC proliferate and migrate to 
the intimal space, building a fibrous cap, while also continuing to express adhesion molecules 
and facilitate macrophage infiltration. An unstable lesion is inclined to rupture and release a 
thrombus, the ultimate complication. 
 
 
Figure 1-1: Stages of atherosclerotic lesion development. 
A. The normal artery contains three layers. The innermost layer is the intima (mainly endothelium with some VSMC 
in humans), followed by the media (VSMC), and surrounded by the outer adventitia (fibroblasts and connective 
tissue). B. Atherosclerosis is initiated by the adhesion of circulating leukocytes to the activated endothelium and 
their migration into the intima. The monocytes mature into macrophages and engulf cholesterol, yielding foam cells.      
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C. VSMC migrate into the lesion and synthesize extracellular matrix components to constitute the fibrous cap. 
Lipid-laden foam cells undergo apoptosis and accumulate in what is known as the necrotic core. D. Thrombosis is 
the ultimate complication of atherosclerosis and is accelerated by a large necrotic core and thin fibrous cap. 
Reprinted with permission from Nature Publishing Group: Nature (7). 
 
1.1.1 Initiation of the Fatty Streak 
Lesions primarily occur in medium- and large-sized muscular and elastic arteries at branches, 
bifurcations, and curvatures where low or oscillatory shear stress is present (6, 8-10). This 
alteration in blood flow stimulates intercellular adhesion molecule 1 (ICAM-1) expression on 
endothelial cells (11, 12), priming the site for the adhesion of inflammatory cells. Low-density 
lipoprotein (LDL) can become trapped in subintimal spaces and undergo progressive oxidation, 
as well as other modifications (13). Exposure to high levels of cholesterol, including oxidized-
LDL (oxLDL), further increases the vessel permeability with the expression of vascular cell 
adhesion molecule-1 (VCAM-1). Adherence of platelets to activated endothelium also enhances 
adhesion molecule expression as well as the release of the chemokine monocyte chemotactic 
protein-1 (MCP-1) in response to lipoproteins (14). MCP-1 and oxLDL attract circulating 
monocytes to this site where they attach to endothelial ICAM-1 and VCAM-1 via β2-and α4β1-
integrins, respectively (15, 16). Using a host of other adhesion molecule-integrin interactions, 
monocytes transmigrate through the intima and eventually the media, led by VSMC-derived 
MCP-1 (17, 18). This contributes to the formation of the fatty streak, the earliest phase of 
atherosclerosis. 
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The fatty streak is a purely inflammatory lesion consisting only of monocyte-derived 
macrophages and T-cells. These lesions are common even in children and adolescents (19) and 
may resolve on their own or continue progressing into more mature plaques. Locally-produced 
macrophage colony-stimulating factor allows the monocytes to survive, replicate, and 
differentiate into macrophages (20, 21). Scavenger receptors on macrophages can internalize a 
broad range of molecules, including oxLDL, and failure to sufficiently undergo cholesterol 
efflux leads to the accumulation of lipid droplets in the cytoplasm (22, 23). Macrophages that are 
overloaded with cholesterol are referred to as foam cells. Furthermore, an overabundance of 
cholesterol is toxic to macrophages and triggers ER stress and apoptosis (24-26). 
1.1.2 Plaque Progression and Rupture 
Macrophages and T-cells accumulate at the “shoulder” region near where plaque meets normal 
tissue (27) and propagate a local inflammatory response inside the vessel wall. Lesional CD4+ 
T-cells are reactive to oxLDL (28), and ligation of the antigen receptor initiates an activation 
cascade culminating in either a type 1 helper (Th1) or type 2 helper (Th2) response. Th1 cells 
secrete pro-inflammatory cytokines such as interferon γ (IFNγ) and tumor necrosis factor α 
(TNFα) and are typically utilized to fight intracellular pathogens. On the other hand, Th2 cells 
secrete interleukin (IL) 4, IL-5, and IL-13 and are more involved in allergic inflammation (29). 
Atherosclerotic lesions contain Th1 cells, which can activate macrophages and augment their 
cytokine generation (i.e. TNFα and IL-1β), in addition to upregulating genes relevant to antigen 
presentation (30). Inhibition of Th1 cells with pentoxifylline, a phosphodiesterase inhibitor 
which reduces the Th1 polarization of T helper lymphocytes, decreases atherosclerotic severity 
in Apolipoprotein E (Apoe)
-/-
 mice (31). However, switching to a strictly Th2 differentiation 
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induces abdominal aortic aneurysms (32), demonstrating that these processes are intricately 
related and not completely black and white. 
Similar to T-cell polarization, macrophages are classified as M1 or M2, although this 
tends to be an oversimplification. “Classically activated” M1 macrophages are pro-inflammatory 
and depend on Th1-produced IFNγ while “alternatively activated” M2 macrophages are 
primarily involved in wound healing and rely on IL-4 or IL-13 secretion from Th2 cells (33). 
Another classification of M2 includes the IL-10-induced regulatory macrophages, which are 
important for resolving inflammation. After IFNγ priming, oxLDL, alone or in immune 
complexes, activates M1 macrophages to produce matrix metalloproteinases (MMPs), tissue 
factor, and cytokines including TNFα, IL-1β, and IL-6 (34-36). Macrophage activation may 
further occur through toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-
like receptors (37). In fact, C3H/H2J mice, which carry a missense mutation in signaling 
domains of Tlr4, are resistant to atherosclerosis (38). Furthermore, cytokines produced by M1 
macrophages can further propagate the inflammatory response through autocrine and paracrine 
signaling.  
Early macrophage apoptosis resulting from cholesterol overload is beneficial as it 
suppresses lesion cellularity, but uncontrolled cell death promotes advanced plaque necrosis. 
Inhibiting apoptosis in macrophages enhances atherosclerosis (39, 40). Apoptotic cells that are 
not cleared by phagocytes become swollen and leaky, resulting in secondary necrosis and the 
formation of the necrotic, or lipid, core (41, 42). Apoptotic cells can shed procoagulant 
membrane microparticles such as tissue factor (43). Tissue factor activity is dependent upon 
phosphatidylserine (44), a phospholipid that is consequently exposed during apoptosis, rendering 
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the necrotic core highly thrombogenic (43, 45, 46). The necrotic core is the most deleterious part 
of the plaque and its encapsulation and separation from the blood flow is critical. 
Advanced lesions are covered by a fibrous cap formed from matrix deposition and the 
proliferation and migration of VSMC. This cap protects the bloodstream from the pro-thrombotic 
interior. Production of transforming growth factor β (TGF-β) by any cell in the atheroma 
stimulates VSMC and fibroblasts to produce collagen, creating a protective scar over the lesion 
(47-49). Additionally, cytokines and growth factors from macrophages and activated 
endothelium, especially platelet-derived growth factor (PDGF), promote VSMC proliferation 
and migration, adding to the collagenous fibrous cap (50). MMPs cleave collagen and elastin to 
facilitate the migration of VSMC through the elastic laminae and collagenous matrix to the 
intimal space (51, 52). However, the matrix-degrading abilities of MMPs also contribute to the 
thinning of fibrous cap, particularly in the shoulder regions (53). IFNγ from Th1 cells can inhibit 
VSMC proliferation and collagen production (48) and VSMC are also susceptible to apoptosis 
(54), further weakening plaque stability.  
The thickening of the arterial wall triggers outward remodeling, and the gradual dilation 
of the vessel delays the onset of flow-limiting stenosis that can lead to ischemia (55, 56). MMPs 
may be involved in this process in order to relieve the structural constraint imposed by the matrix 
(57). While initially beneficial, positive remodeling may also contribute to plaque instability. 
Larger, outward remodeled plaques are associated with unstable clinical presentation (58). 
Dilation of these arteries may in fact weaken them and make them mechanically vulnerable to 
plaque rupture. 
An unstable plaque is typically characterized by a thin fibrous cap, large necrotic core, 
and a substantial inflammatory cell infiltrate. When a plaque ruptures, procoagulants in the 
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bloodstream come into contact with tissue factor in the necrotic core and generate a thrombus. 
The thrombus can locally impede blood flow or dislodge and travel through the circulation as an 
embolus, eventually becoming lodged in another artery. This obstruction causes tissue ischemia, 
stroke, and myocardial infarction. Occlusive thrombi from ruptured plaques account for almost 
one-third of sudden coronary deaths (59). Surprisingly, plaque rupture is not always fatal (60) 
and the possibility exists that a thrombus can be resorbed into the plaque (61). Intraplaque 
hemorrhage can also occur as a result of leakage of the vasa vasorum or other plaque neovessels 
that oxygenate advanced plaques (62). However, both mechanisms of a non-fatal rupture 
contribute to plaque growth and may still lead to occlusion of the vessel. 
1.1.3 Resolution of Inflammation 
An inflammatory response can continue indefinitely if the offending source is not eliminated. 
Effective resolution of inflammatory processes requires the inhibition of inflammatory cell 
recruitment, clearance of apoptotic cells (efferocytosis), and promotion of inflammatory cell 
egress. Defects in the resolution of inflammation promote the formation of vulnerable plaques. 
Consequently, these functions and other anti-inflammatory signaling events are often impaired in 
atherosclerosis. 
1.1.3.1 Anti-Inflammatory Mediators 
There are a number of anti-inflammatory mediators that attempt to dial back the 
inflammation before it progresses to a dangerous level. These include IL-10, TGFβ, lipid 
mediators, and the liver X receptor (LXR) transcription factor. IL-10 targets leukocytes and 
induces suppressor of cytokine signaling (SOCS) 3, inhibiting pro-inflammatory nuclear factor 
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κB (NF-κB) signaling (63, 64). Additionally, the cytokine enhances macrophage efferocytosis 
(65) and its overexpression in lymphocytes decreases atherosclerotic severity in mice (66). In 
human cases of atherosclerosis, serum IL-10 levels are decreased and inversely related with 
future myocardial infarctions (67). 
Lipid mediators such as 12,15-lipoxygenase and prostaglandin E2 also have a role in 
lesional inflammation. Global deficiency of 12,15-lipoxygenase in Apoe
-/-
 mice aggravates 
atherosclerosis while overexpression of the enzyme in macrophages is atheroprotective (68). 
These effects are mediated through the synthesis of lipoxin A4, protectin D1, and resolvin D4, 
resulting in attenuated cytokine, chemokine, and adhesion molecule expression and increased 
phagocytic activity (68). A product of the cyclooxygenase pathway, prostaglandin E2 suppresses 
macrophage production of inflammatory cytokines while enhancing IL-10 production (69). 
Furthermore, Ldlr
-/-
 mice receiving bone marrow deficient in EP4, the receptor for prostaglandin 
E2, exhibit reduced early atherosclerosis (70). This is due to the suppression of pro-survival 
pathways and increased apoptosis of macrophages that would otherwise initiate atherosclerosis. 
Activation of the LXR family of transcription factors is also atheroprotective. LXR 
agonists induce expression of cholesterol transporters such as ABCA1 and ABCG1 to promote 
cholesterol efflux in foam cells (71).  Like most other anti-inflammatory mediators, these nuclear 
receptors repress expression of pro-atherogenic molecules (72). Finally, LXR family agonists 
induce a marked reduction in plaque formation in mouse models of atherosclerosis (73). 
1.1.3.2 Monocyte Recruitment 
 There is persistent recruitment of new macrophages throughout the lifetime of the plaque 
due in part to the hypercholesterolemia-induced increase in the number of circulating Ly6C
hi
 
monocytes (M1 precursors) (74, 75). This increase comes as a consequence of enhanced survival 
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and impaired conversion of Ly6C
hi
 monocytes to their Ly6C
lo
 counterparts (74). A decrease in 
plaque-derived MCP-1 is observed following the transplant of plaque-bearing region of the aorta 
from atherosclerotic Apoe
-/-
 mice to wild-type mice, demonstrating that a decrease in the 
surrounding cholesterol levels could stifle macrophage recruitment (76).  
1.1.3.3 Macrophage Egress 
Egress of inflammatory cells is similarly impaired in the presence of 
hypercholesterolemia. However, plaque transfer from lipid-laden mice to normal mice not only 
results in lesion regression but emigration of inflammatory cells out of the vessel wall (77). 
Resident macrophages differentiate into migratory dendritic cells and emigrate to the lymph 
nodes in a CC-chemokine receptor 7-dependent manner (76, 77). This suggests that the lowering 
of cholesterol levels is central to proper resolution of inflammation. 
1.1.3.4 Efferocytosis 
Efferocytosis, the removal of apoptotic cells by phagocytes, is effective in early lesions, 
but as the disease progresses and more cells undergo apoptosis the plaque becomes necrotic. 
Indeed, efferocytosis is defective in advanced lesions (78). Not only is it advantageous to clear 
out dying cells, but phagocytosis of apoptotic cells inhibits pro-inflammatory cytokine 
production through the release of TGF-β (79). TGF-β additionally inhibits MCP-1 expression 
and further macrophage recruitment (80). 
Foam cells undergoing apoptosis secrete “find me” factors, such as 
lysophosphatidylcholine, and membrane-bound “eat me” signals, including phosphatidylserine, 
to attract phagocytes (81). Phagocytes express a specific set of molecules that bridge the 
interaction with the apoptotic cells. For example, αVβ3 integrin and C-MER proto-oncogene 
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tyrosine kinase (MERTK) on phagocytes contact milk fat globulin E8 (MFGE8) and growth 
arrest-specific protein 6 (GAS6) on apoptotic cells, respectively (82, 83). Disrupting these 
interactions leads to an accumulation of apoptotic cells and accelerates atherosclerosis (84, 85). 
 There are many hypotheses as to what could be causing faulty efferocytosis in developing 
atheromas. One possibility is that the phagocytes are simply overwhelmed by the sheer number 
of cells that need to be cleared. However, individual phagocytes have a high capacity for 
efferocytosis and there are plenty of macrophages that are capable of the job, even with the high 
death rate. Foam cells are still able to engulf apoptotic cells (86) so the pool of competent 
phagocytes is adequate. Furthermore, phagocytes are highly resistant to cholesterol-induced 
death due to massive cholesterol efflux and the activation of NF-κB and Akt survival pathways 
after foam cell ingestion (87). A likely possibility is that the bridging molecules are somehow 
deficient in function or expression in advanced plaques. Cleavage of the ectodomain of MERTK 
in response to pro-inflammatory stimuli inhibits apoptotic cell clearance (88). In addition to the 
now-dysfunctional MERTK left in the membrane, the soluble portion of MERTK binds and 
sequesters GAS6, creating competition for intact MERTK (88). Inflammation can also 
downregulate MFGE8 expression similarly affecting efferocytosis (89).  
Cellular age may also explain the defect in efferocytosis as the majority of deaths 
attributed to CVD occur after the age of 75 (2). Macrophages extracted from old mice (2 years) 
and humans (between 65 and 90 years) display a diminished ability to clear apoptotic cells (90, 
91). Additionally, monocyte-derived dendritic cells from older subjects secrete higher levels of 
TNFα and IL-6 in response to inflammatory stimuli (90). Interestingly, pre-treatment of 
macrophages with serum from aged mice also reduces efferocytosis in comparison to treatment 
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with serum from young mice, suggesting the presence of an inhibitory factor or absence of an 
effector in aged serum (91).  
1.1.4 Risk Factors 
1.1.4.1 Hyperlipidemia 
While a number of different factors can initiate atherosclerosis, the most obvious culprit is high 
cholesterol levels (92). As detailed above, modified lipids trapped in the intima can stimulate the 
expression of adhesion molecules, proinflammatory cytokines, chemokines, and other mediators 
in T-cells, macrophages, VSMC, and endothelial cells. Certain growth factors and cytokines such 
as PDGF, TGFβ, TNFα, and IL-1β can induce LDL receptor (LDLR) expression and thus 
promote LDL uptake (93-95). Therefore, as long as there is excess modified cholesterol present, 
a vicious cycle is maintained between lipoprotein uptake and inflammation. Antioxidants vitamin 
E and probucol can reduce the oxidative propensity of LDL and reduce the size and severity of 
atherosclerotic lesions without lowering lipid levels (96-98). 
Patients with familial hypercholesterolemia, a genetic disorder characterized by high 
levels of cholesterol and caused primarily by mutations in the LDLR gene are at an increased risk 
of early-onset coronary heart disease without treatment (99). A popular treatment for those with 
familial hypercholesterolemia and others with high cholesterol is HMG-CoA reductase inhibitors 
(rate limiting in cholesterol synthesis), or statins. Statins are currently the main class of drugs 
used in the treatment of atherosclerosis. Consequently, the reduction in cholesterol synthesis by 
statins has prominent anti-inflammatory effects, reducing adhesion molecules, MMPs, tissue 
factor, and IFNγ and other cytokine production (100-102). 
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1.1.4.2 Obesity and Diabetes 
Obesity is a worldwide epidemic affecting multiple organ systems, including the cardiovascular 
system, and was reclassified by the American Heart Association as a “major, modifiable risk 
factor” for coronary heart disease (103, 104). For each additional unit of body mass index , the 
risk of atherosclerosis increases by 8% (105). Like atherosclerosis, obesity is characterized by 
dyslipidemia, although the profile is different. While high LDL levels contribute to CVD, obesity 
is characterized by higher levels of very low-density lipoprotein, triacylglycerols, and total 
cholesterol with a decrease in high-density lipoprotein levels (106). For this reason, obese 
individuals require a more intensive course of statin treatment to impact plaque regression than 
those with a lower body mass index (107).  
Adipose tissue is an active autocrine and paracrine organ that secretes “adipokines” to 
regulate different metabolic and vascular processes. Two prominent examples of adipokines that 
are dysregulated in obesity and other insulin-resistant states are leptin and adiponectin. Instead of 
a normal balance, leptin and most other adipokines are increased while levels of the normally 
anti-atherogenic adiponectin are decreased. Adiponectin can reduce VSMC proliferation and 
migration in addition to inhibiting MMPs following induction of IL-10 (108, 109). This suggests 
that adiponectin could protect against plaque rupture. Adiponectin could potentially guard 
against endothelial dysfunction as the adipokine can also inhibit adhesion molecule expression 
and foam cell formation (110, 111). Increased plasma concentrations of TNFα are correlated 
with reduced adiponectin levels (112) and many speculate that this is a more causative 
relationship. On the other hand, leptin is pro-thrombotic and stimulates VSMC proliferation and 
migration (113, 114). 
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Hyperglycemic disorders stemming from obesity such as diabetes can initiate pro-
inflammatory states through non-enzymatic formation of heterogeneous advanced glycation end 
products (AGE). AGE modification of macromolecules in the extracellular matrix (i.e. collagen) 
results in crosslinking and increased arterial stiffness. In addition, this can trap oxLDL within the 
vessel wall (64). In contrast, binding of AGE to the receptor for AGE (RAGE) increases 
cytokine production, VSMC proliferation and migration, adhesion molecule expression, and 
reactive oxygen species in the vasculature (115). Furthermore, AGE-RAGE increases foam cell 
formation and inhibits cholesterol efflux, contributing to the progression of atherosclerosis (115). 
1.1.4.3 Infection  
While there is no direct evidence that infectious agents can induce atherosclerosis by themselves, 
microorganisms such as cytomegalovirus and Chlamydia pneumonia can accelerate lesion 
development in conjunction with other factors (116). C. pneumonia stimulates adhesion 
molecule and cytokine expression in endothelial cells, VSMC, and macrophages (117). These 
agents can release lipopolysaccharides (LPS) into the bloodstream and the reduction of 
atherosclerosis in a Tlr4/Apoe double knockout mouse model indicated a role for infections in 
CVD (118). LPS signals through TLR4, but oxLDL is also able to bind this receptor, 
complicating the results. Many plaques show signs of infection by cytomegalovirus and C. 
pneumonia (119, 120), but administration of antibiotics has no effect on prevention of CVD 
(121).     
1.1.4.4 Other Factors 
Not only is cigarette smoke a teratogen that increases risk for lung cancer, but the 
nicotine and other toxins inhaled can induce endothelial dysfunction and accelerate 
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atherogenesis. Cigarette smoke can cause an increase in soluble ICAM-1 in the plasma, a 
biomarker for myocardial infarction risk and sign of endothelial dysfunction (122, 123). 
Furthermore, cigarette smoke activates macrophages, a possible mode for the pro-atherogenic 
insulin resistance and decrease in adiponectin levels seen in chronic smokers (124-126). 
Elevated concentrations of the vasoconstrictor angiotensin II (AngII), a major contributor 
to hypertension, can initiate vascular inflammation.  In addition to contraction and hypertrophy, 
AngII stimulates VSMC to express IL-6, MCP-1, and VCAM-1 (127-129). Hypertension can 
also induce oxidative stress in the arterial wall (63). 
1.1.5 Restenosis 
Significant stenosis is usually defined as a greater than 75% reduction of cross-sectional 
area of the lumen (59). The current methods to circumvent arterial blockages, such as balloon 
angioplasties and stents, compress plaques and widen the artery but often result in 
counterproductive re-narrowing of the vessel (restenosis). With a simple balloon angioplasty, 
restenosis occurs in 30-60% of patients. The introduction of the bare-metal stents reduced the 
reoccurrence to 16-44%, while drug-eluting stents (i.e. sirolimus, paclitaxel) are even further 
improved with 0-16% (130). However, these stents are less efficacious in diabetics compared to 
non-diabetic patients (131, 132). 
Restenosis features a hyperactive wound-healing response and, aside from foam cell 
formation, highlights many of the same proliferative and inflammatory processes as 
atherosclerosis. In a process known as denudation, the protective endothelial lining is removed, 
damaging the underlying vascular layer and setting into motion an array of events that lead to 
neointima formation. Immediately following vascular injury, a deposit of platelets forms on the 
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denuded surface of the vessel and release PDGF and other growth factors to the VSMC below to 
stimulate migration (133). Leukocytes are recruited to the platelet layer and migrate through to 
the medial VSMC, secreting cytokines and growth factors (6). NAD(P)H-derived reactive 
oxygen species also promote VSMC proliferation and migration (134). The surge of VSMC 
proliferation, due to the release of these stimulants, continues for two weeks post-injury in 
rodents (135). Migratory adventitial fibroblasts may also contribute to neointima formation 
(136).  
Normally, VSMC proliferate at a very low rate, less than 0.1% per day (137). After 
stimulation with numerous growth factors and cytokines, as well as tensile stress from the 
balloon or stent, VSMC undergo a switch from a contractile phenotype to a synthetic phenotype. 
This is evidenced by cellular hypertrophy, increased proliferation and migration, and a decreased 
ability to contract (138). These dedifferentiated VSMC are also stimulated to synthesize matrix 
components, such as collagen, leading to increased extracellular matrix. In order to allow 
continued migration of VSMC from the media to intima, there is an increase in plasminogen 
activators and matrix metalloproteinases which degrade the surrounding matrix (139). Even 
though the VSMC stop proliferating after two weeks, the neointima continues to grow through 
increased cell volume and extracellular matrix deposits (137). 
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1.2 NUCLEAR FACTOR-KAPPA B 
1.2.1 Introduction to NF-κB 
NF-κB was originally described over 25 years ago as an essential DNA-binding complex for 
immunoglobulin kappa light chain transcription (140). This family of transcription factors 
consists of five subunits that may homo- or heterodimerize: RelA/p65, RelB, c-Rel, p50, and 
p52, where p65/p50 is the classical example. These proteins share a highly conserved 300-
amino-acid Rel homology domain which is responsible for dimerization, DNA binding, and 
interactions with ankyrin repeats in inhibitors of κB (IκB) (141, 142). NF-κB also contains a 
nuclear localization sequence (NLS). The C-terminal halves of p65, RelB, and c-Rel contain a 
transactivation domain (TAD) for transcriptional activity, while the pre-processed forms of p50 
and p52 instead have ankyrin repeats typical of the IκB family. Subunits p50 and p52 are 
generated by proteolytic cleavage of p105 and p100, respectively. 
Active NF-κB exists as a dimer, although not all combinations of the five subunits occur. 
The ubiquitous example is p65/p50, while RelB only dimerizes with p50 or p52 (143). The 
p50/p50 homodimer lacks transactivational activity and instead binds to κB promoter regions or 
recruits deacetylases to inhibit κB-dependent transcription (144), although emerging evidence 
suggests that it may in fact positively influence certain gene transcription (145, 146). Each dimer 
possesses distinct properties including binding site preference, activation, subcellular 
localization, and tissue specificity, allowing for differential gene regulation (147, 148). In this 
text I will focus on the classical p65/p50 heterodimer and refer to it as NF-κB from now on. 
At least 150 different stimuli activate the transcription factor, and in turn NF-κB controls 
transcription of at least as many genes (149). These stimuli include inflammatory mediators, 
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antigen receptor engagement, bacterial and viral infections, UV irradiation, and oxidative stress 
(148). Cell growth, proliferation, and survival is largely dependent on NF-κB for the 
transcription of anti-apoptotic genes (inhibitor of apoptosis proteins, Bcl family members), 
growth factors, and cyclins (150-153).  Genetic ablation of p65 is embryonic lethal, further 
substantiating the importance of NF-κB in growth and development (154). NF-κB-dependent 
transcription of cytokines, chemokines, adhesion molecules, and acute phase proteins also 
regulates inflammatory processes (149). Not surprisingly, deregulation of NF-κB results in 
diseases such as cancer, autoimmunity, immunodeficiency, and chronic inflammatory diseases 
including asthma, rheumatoid arthritis, and inflammatory bowel syndrome (155, 156).  
1.2.2 The NF-κB Signaling Pathway 
Traditionally, inactive NF-κB is sequestered in the cytoplasm by members of the IκB family, 
most notably IκBα (157). However, even though IκBα masks the NLS of p65, the NLS of p50 is 
still accessible (158). In conjunction with the nuclear export sequence on IκBα, this results in the 
shuttling of the NF-κB:IκBα complex between the cytoplasm and the nucleus, although the 
cytoplasm is heavily favored in the steady-state localization (159, 160). Upon stimulation, 
upstream signals rapidly converge on the phosphorylation and induction of the multi-subunit IκB 
kinase (IKK) complex. Figure 1-2 illustrates the general activation pathway of NF-κB. 
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Figure 1-2: General activation of NF-κB. 
NF-κB is basally sequestered in the cytoplasm by IκBα. Upon activation, upstream signals converge on IKK 
activation, resulting in the phosphorylation and degradation of IκBα. NF-κB is now able to translocate to the nucleus 
and stimulate gene transcription. 
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The IKK complex includes two catalytic subunits, IKKα and IKKβ, and the 
regulatory/scaffolding subunit IKKγ/NEMO (161). IKKα plays a minor role in this pathway and 
is more important for non-canonical activation of NF-κB-inducing kinase and RelB/p52 in 
response to B-cell activating factor, lymphotoxin-β, or CD40 ligand (162). In response to 
activators of the canonical pathway (i.e. TNFα, LPS, IL-1β), activation of the β subunit of the 
IKK complex results in the phosphorylation of S32/36 on IκBα and its subsequent proteosomal 
degradation, exposing the NLS of NF-κB and permitting its nuclear translocation (163, 164). 
Newly synthesized IκBα, one of the earliest induced NF-κB targets, can enter the nucleus and 
export NF-κB back to the cytosol as one method of terminating transcription (165, 166). Here I 
will briefly focus on the basics of the classical signaling pathways of TLR4/IL-1 receptor (IL-
1R) (receptors for LPS and IL-1β, respectively) and TNF-R1 (receptor for TNFα). 
Although their extracellular domains differ, IL-1R and TLR4 both contain intracellular 
TLR/IL-1R (TIR) domains. Upon binding IL-1β, the IL-1R accessory protein (IL-1RAcP) and 
myeloid differentiation primary response gene 88 (MyD88) are recruited to the TIR domain of 
IL-1R, followed by IL-1R associated kinase (IRAK) 1, Tollip, TNF receptor-associated factor 
(TRAF) 6, and IRAK-4 (167-170). Auto-phosphorylation activates IRAK-4 (171), leading to 
subsequent phosphorylation and activation of IRAK-1 (172). Hyperphosphorylation of IRAK-1 
dissociates the kinase from Tollip and MyD88, but not TRAF6 (172). The dissociated IRAK-
1/TRAF6 complex interacts with a pre-formed membrane complex consisting of 
TAK1/TAB1/TAB2 (173). This complex translocates to the cytoplasm but leaves IRAK-1 
behind at the membrane for poly-ubiquitination and degradation (173, 174). However, the 
degradation of IRAK-1 is debatable and could be cell-specific (173, 175). In the cytoplasm, 
TRAF6 interacts with Ubc13/Uev1A, an E2 ubiquitin-conjugating enzyme complex, and 
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undergoes auto-poly-ubiquitination by K63-linked ubiquitin chains (176). This prompts the poly-
ubiquitin binding of TAB2 and the activation of TAK1, which subsequently phosphorylates 
IKKβ (177).  
Generally, signaling through TLR4 is similar to IL-1R with few variations (Figure 1-3). 
LPS first binds CD14 before transfer to MD-2 and TLR4 (178, 179). Recruitment of MyD88 to 
the receptor is instead dependent on TIRAP/Mal (180) and BCL10 and MALT1 are inserted in 
the pathway (181). In addition, there is a MyD88-independent pathway stemming from TLR4 
activation. TLR4 can associate with the adaptor proteins TRIF and TRAM in early endosomes to 
induce delayed NF-κB and IRF-3 activation, although there is no expression of the classical 
inflammatory genes (182, 183). 
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Figure 1-3: LPS signaling to NF-κB. 
LPS, in complex with LPS-binding protein (LBP), binds CD14 and is transferred to MD-2 and TLR4. A. MyD88 is 
recruited to the receptor complex via Mal. The addition of Tollip, IRAK-1, IRAK-4, and TRAF6 form Complex I. 
Complex formation triggers IRAK-4 autophosphorylation and the phosphorylation of IRAK-1. IRAK-1 and TRAF6 
leave the complex and associate with a pre-formed complex of TAK1/TAB1/TAB2/3 at the membrane (Complex 
II). IRAK-1 is poly-ubiquitinated and degraded. The new Complex III leaves the membrane and interacts with 
Ubc13/Uev1A. This results in the ubiquitination of TRAF6, TAB2 binding, and TAK1 activation, leading to IKK 
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phosphorylation and NF-κB activation. B. TLR4 also features a MyD88-independent pathway. TRAM and TRIF are 
recruited to endosomal TLR4. TRIF is associated with RIP1, whose poly-ubiquitination interacts with poly-
ubiqutinated TRAF6 and the TAK1/TAB1 complex to induce late-phase NF-κB activation. TRIF can also initiate 
type 1 interferon induction through the activation of TBK1, IKKε, and IRF3. 
Reprinted with permission from Springer: Cellular and Molecular Life Sciences (184). 
 
 
Like TLR4, TNF-R1 signals through distinct pathways at the membrane and after 
endocytosis (Fig. 1-4). TNF-R1 trimerizes in response to TNFα and interacts with TRADD 
through its death domains. TRADD recruits TRAF2, which undergoes K63-linked poly-
ubiquitination, and receptor interacting protein (RIP), which also interacts with TRAF5 (185-
187). TRAF2 similarly ubiquitinates RIP via K63-linked poly ubiquitin chains (188). The 
TAK1/TAB1/TAB2 complex interacts with these poly-ubiquitin chains, activates TAK1, and 
phosphorylates IKKβ (189, 190). 
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Figure 1-4: TNFα signaling to NF-κB. 
TNF-R1 trimerizes in response to TNFα stimulation and recruits TRADD through its death domain. TRADD 
dimerizes and binds TRAF2 and RIP1, which also interacts with TRAF5. TRADD dissociates from TNF-R1 during 
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endocytosis and interacts with FADD, leading to caspase-8 recruitment. This initiates proapoptotic signaling. 
Meanwhile, TRAF2 undergoes auto-poly-ubiquitination and subsequently ubiquitinates RIP1. A. Poly-ubiquitinated 
RIP1 recruits TAB2 and IKKγ, which respectively interact with TAK1 and IKKβ, leading to NF-κB activation. B. 
RIP1 can also recruit MEKK3, which phosphorylates IKKβ. C. RIP1 can also interact with p62to activate atypical 
PKCs, leading to IKKβ phosphorylation. 
Reprinted with permission from Springer: Cellular and Molecular Life Sciences (184). 
 
 
However, NF-κB activation is not always completely abrogated in TAK1-deficient cells 
(191, 192), suggesting the possibility of TAK1-independent routes of IKKβ activation. MEKK3 
and protein kinase C (PKC) ζ are likely candidates to fill this role. After TNFα stimulation, 
MEKK3 can phosphorylate IKKβ independent of TAK1 (193). In contrast, MEKK3 activation in 
response to IL-1β involves phosphorylation of IKKα and IKKγ, not IKKβ, and subsequent 
phosphorylation and dissociation of IκBα from NF-κB (194). On the other hand, PKCζ is also 
implicated in IKK activation and will be covered in detail in a later section. 
1.2.2.1 Post-Translational Modifications of p65 
In order to elicit a maximal NF-κB response, the p65 subunit is additionally subjected to 
phosphorylation, acetylation, and ubiquitination. This extra layer of regulation influences the 
ability of NF-κB to recruit and interact with coactivators, bind DNA, and reassociate with IκBα.  
The p65 subunit has a protein kinase A (PKA) consensus site at S276 within the Rel 
homology domain and coincidentally the catalytic subunit of PKA is included in the cytoplasmic 
NF-κB:IκBα complex (195). Degradation of IκBα activates PKAc, phosphorylating p65 at S276 
and enhancing p65 binding to both DNA and the transcriptional coactivator p300/CREB-binding 
protein (CBP) (144, 196). Normally folded in a closed conformation, S276 phosphorylation 
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disrupts the inhibitory intramolecular interaction within p65 and exposes the binding sites for 
DNA and p300/CBP. Mitogen- and stress-activated protein kinase (MSK) 1 and MSK2 have 
identical substrate specificity to PKA and can also phosphorylate p65 at S276 (197). The only 
difference lies within subcellular localization since MSK1/2 are nuclear proteins. How the two 
kinases cooperate with cytosolic PKA is still unknown. 
Additional p65 phosphorylation sites at S536 and S529 in the C-terminal TAD have been 
studied but are not as well characterized as S276. IKKα, IKKβ, ribosomal S6 kinase 1 (RSK1), 
and TANK-binding kinase 1 have all been implicated in phosphorylation of p65 at S536 (198-
201). Phosphorylation of this residue is required for full NF-κB activity (202, 203). In contrast to 
other mechanisms of NF-κB induction, activation of p53 in response to DNA damage activates 
RSK1 and phosphorylates S536 in an IKK/IκBα-independent manner (201). This modification 
results in decreased affinity of p65 for IκBα, shifting the steady state localization of p65 to the 
nucleus and increasing its transactivational activity (201). It is not known whether 
phosphorylation of S536 by other kinases has similar effects. Casein kinase II (CKII) is the lone 
kinase implicated in the phosphorylation of S529 (204-206). Although CKII is not activated 
upon TNFα stimulation, it readily phosphorylates cytoplasmic p65 upon IκBα degradation and 
increases its transactivational potential (204, 205). However, others failed to find evidence 
supporting a role for S529 in NF-κB activity (202). In addition, p65 is a target for protein 
phosphatase 2A (PP2A) and the dephosphorylation of these serines could contribute to NF-κB 
inhibition (207, 208). 
Inhibitory phosphorylation sites also exist within the TAD of p65. Activation of 
checkpoint kinase Chk1 by the ARF tumor suppressor or the chemotherapeutic drug cisplatin 
phosphorylates T505 and increases the association of p65 with histone deacetylases (see below) 
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(209, 210). This results in the repression of some anti-apoptotic genes including Bcl-xL. 
Phosphorylation of T435 also negatively regulates NF-κB activity, although the kinase is 
unknown (211). The TAD of p65 is important for binding to coactivators, so these inhibitory 
phosphorylations most likely regulate such associations. 
Like phosphorylation, inducible acetylation of p65 provides both positive and negative 
levels of regulation. Acetylation of K218, -221, and -310 promote NF-κB activity while 
K122/123 function in an inhibitory role. K221 acetylation enhances p65 binding to DNA and, 
alone or together with K218 acetylation, inhibits the association of p65 with newly synthesized 
IκBα and retains the complex in the nucleus (212). Additionally, acetylation of K310 stimulates 
transactivational activity of NF-κB independent of DNA-binding and IκBα complex assembly, 
possibly through interactions with other coactivators (212). Furthermore, a link between p65 
phosphorylation and acetylation exists in which S276 and S2536 phosphorylation leads to 
increased association of p65 with p300/CBP, resulting in enhanced acetylation (213). 
Deacetylation of these lysines by histone deacetylase 3 and sirtuin 1 results in the dissociation of 
p65 from κB sites and IκBα-dependent removal from the nucleus (214, 215). Conversely, 
K122/123 acetylation inhibits p65:DNA interactions and facilities its export from the nucleus 
(216).  
Lastly, p65 is subject to inducible ubiquitination by the E3 ubiquitin ligases PDLIM2, 
SOCS1, and COMMD1. PDLIM2 binds, polyubiquitinates, and mediates targeting of p65 to 
PML bodies within the nucleus where it is degraded by the proteasome (217). SOCS1 is part of a 
complex that can couple to COMMD1 in response to stimulation (218). This association 
stabilizes the SOCS1-p65 interaction and also facilitates the ubiquitination of the transcription 
factor (218). These events result in the degradation and termination of NF-κB signaling. 
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1.2.2.2 Termination 
While NF-κB is able to self-propagate through feed-forward and amplification loops to 
produce beneficial inflammation for healing and repair within the body, it is just as important 
that it terminates the cycle before it becomes excessive and causes damage. Negative feedback 
mechanisms are rapidly induced but allow for at least one round of uninhibited activation before 
their own induction. There are many other modes of turning off NF-κB activity in addition to 
newly synthesized IκBα and the post-translational modifications of p65 already described. These 
mechanisms target various steps of the signaling pathway and include interfering with receptor 
function, production of dominant-negative signaling proteins, reversal of post-translational 
modifications, and inhibition of nuclear p65 (219).  
The IL-1 receptor and TLR4 are targeted by the nonfunctional receptor mimics ST2 and 
RP105, respectively. ST2 is produced in two forms, soluble secreted ST2 and transmembrane 
ST2. Soluble ST2 functions as a decoy receptor to IL-1 while transmembrane ST2 lacks a TIR 
domain and inhibits IL-1 receptor and TLR4 by competing for MyD88 binding (220). RP105, 
which also lacks a TIR domain and is unable to transduce signals, interacts with TLR4 and 
inhibits LPS binding (221).  
Dominant-negative signal transducers can arise from splice variants or as a cell-specific 
response. Unlike the ubiquitous IRAKs, expression of IRAK-M is restricted to monocytes and 
macrophages (222). Rapidly induced upon TLR4 signaling, the kinase-dead IRAK-M prevents 
dissociation of IRAK and IRAK-4 from MyD88, effectively inhibiting NF-κB activation (223). 
Similarly, IRAKc is a splice variant that lacks exon 11, part of the kinase domain, and thus 
kinase activity. IRAKc still retains the ability to interact with IRAK2, MyD88, Tollip, and 
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TRAF6, but is unable to be phosphorylated by IRAK4 (224). Another example is a truncated 
form of MyD88, MyD88s, which fails to recruit IRAK4 (225). 
An interesting protein induced after NF-κB activation is A20, an enzyme that features 
dual ubiquitin-editing functions. A20 is a deubiquitinase for K63-linked polyubiquitination of 
TRAF6, NEMO, and RIP (226-228). Other deubiquitinating enzymes important for the 
termination of NF-κB activation include Cezanne and Cyld (229, 230). Conversely, A20 
functions as an E3 ubiquitin ligase for K48-linked degradative polyubiquitination of RIP (226). 
Both actions of A20 result in the suppression of NF-κB signaling upstream of the IKK complex. 
Further downstream in the pathway, nuclear proteins are able to inhibit p65 binding to 
target promoters. The IκB family member IκBζ, induced upon stimulation, interferes with NF-κB 
binding to DNA without affecting nuclear translocation (231). In addition, IKKα activation 
phosphorylates PIAS1, enabling its association with NF-κB promoters and inhibition of a subset 
of genes (232).  
1.2.3 Involvement of PKCζ in NF-κB Activation 
PKCζ is a serine/threonine kinase classified as an atypical member of the PKC family. The 
structure of a PKC family member can be divided into the N-terminal regulatory region and the 
C-terminal kinase domain. The ten members of the kinase family can further be classified 
according to the topology of their regulatory domains: classical, novel, or atypical. Classical 
PKCs (PKCα, βI, βII, γ) contain a diacylglycerol-responsive conserved region 1 (C1) as a 
tandem repeat that is structurally represented as a double zinc finger, in addition to a C2 domain 
that senses calcium (233, 234). Novel PKCs (PKCδ, ε, η, θ) are activated by diacylglycerol but 
are calcium-independent while atypical PKCs (PKCζ and λ/ι) are insensitive to both, containing 
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a single C1 domain and lacking the C2 altogether (235). Instead, atypical PKCs have a 
Phox/Bem1 domain that connects them to Phox/Bem1-containing proteins such as p62 (236). 
PKCζ is naturally inactive because its substrate-binding pocket in the kinase domain is 
auto-inhibited by the regulatory pseudosubstrate (237). Although not responsive to phorbol 
esters, other lipids such as phosphatidylinositols (238), phosphatidic acid (239), ceramide, and 
arachidonic acid (240) can activate PKCζ, presumably through release of the pseudosubstrate 
from the binding pocket. Indeed, overexpression or induction of phosphatidylinositol-3-OH 
kinase (PI3K) increases phosphatidylinositol 3,4,5-trisphosphate  (PIP3) production and activates 
PKCζ (238, 241). Phosphoinositide-dependent kinase 1 is activated after its pleckstrin homology 
domain binds PIP3, and it is this kinase that phosphorylates the T410 priming site in the 
activation loop of PKCζ (242, 243). Autophosphorylation of T560 renders PKCζ catalytically 
competent (244). 
PKCζ is a crucial regulator of the NF-κB pathway. In response to TNFα, IL-1β, and LPS, 
PKCζ is phosphorylated and translocated to the plasma membrane (241, 245-250). 
Overexpression of PKCζ activates NF-κB, even in the absence of stimuli, and a kinase-dead 
mutant inhibits this (245, 251, 252). A key binding partner of PKCζ is zeta-interacting protein 
(ZIP)/p62 (236). ZIP/p62 scaffolds PKCζ to TNF-R1 complexes including RIP and TRAF2, and 
additionally links the kinase to the IL-1R signaling complex with TRAF6 (247, 253). Although 
not yet directly examined, PKCζ may phosphorylate IRAK-1 in these complexes (254, 255). 
Activated PKCζ can also directly phosphorylate IKKβ but not α, serving as a TAK1 substitute 
(245). However, while PKCζ is necessary for NF-κB transcriptional activity in embryonic 
fibroblasts, it has no effect on IKK activation (246). On the other hand, PKCζ is essential for 
IKK activation in the lungs of these mice, demonstrating a cell-specific role for PKCζ in this step 
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of the pathway (246). In addition to upstream functions, PKCζ also phosphorylates S311 on the 
p65 subunit (256). Phosphorylation of S311 is necessary for transactivational activity and 
binding to p300/CBP but has no effect on DNA binding (256). 
1.2.4 NF-κB in the Vasculature  
NF-κB activation lies downstream of many factors implicated in vascular diseases including 
hypoxia, metabolic factors (homocysteine, AGE), infectious agents, T-cell activation, and 
cytokines (257). Modified LDL can induce NF-κB , but longer exposure suppresses its activation 
(19). This may contribute to the apoptosis of foam cells. Activated NF-κB is present in 
endothelial cells, macrophages, and VSMC within the atherosclerotic plaque, and controls the 
expression of many key inflammatory features of macrophage recruitment and adhesion, VSMC 
proliferation, and fibrous cap integrity (149, 258).  
Endothelial cells and VSMC express NF-κB-dependent proteins such as MCP-1 to attract 
leukocytes to the injured area as well as the adhesion molecules ICAM-1, E-selectin, and 
VCAM-1 to facilitate the attachment and transmigration of the leukocytes along the vascular 
wall (18, 149). NF-κB is central to VSMC proliferation and survival, mainly by the induction of 
anti-apoptotic proteins (127, 129, 259). MMPs are upregulated to degrade the surrounding 
extracellular matrix for migrating VSMC and inhibition of NF-κB abolishes the procoagulant 
activity of tissue factor (20-22). Other proteins increased by NF-κB include inducible nitric oxide 
synthase (iNOS), PAI-1, and COX-2, which further mediate the progression of inflammation 
(149). Of course, many cytokines such as IL-1β and TNFα are also NF-κB-dependent and can 
create a positive feedback loop to further activate NF-κB (149, 257).  
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Many studies have established a role for NF-κB in vascular pathologies. Basal NF-κB in 
the rat carotid is low, but after balloon injury there is degradation of IκBα and an upregulation of 
NF-κB genes VCAM-1 and MCP-1 (260). Administration of an IκBα adenovirus during an 
angioplasty in rabbits decreased ICAM-1 and MCP-1 expression as well as macrophage 
recruitment and lumen narrowing (261). Similarly, transfection of NF-κB antisense 
oligonucleotides into a balloon-injured rat carotid artery inhibits neointima formation along with 
ICAM-1 and VCAM-1 expression and leukocyte infiltration (92). Additionally, activated NF-κB 
is present in atherosclerotic lesions (262, 263) and broad inhibition of NF-κB is correlated with 
an overall attenuation of atherosclerosis (128, 264, 265).  
Surprisingly, NF-κB is also involved in the resolution of inflammation. Macrophage-
specific deletion of IKKβ enhances atherosclerosis in Ldlr-/- mice (266). These macrophages 
present with a reduced early inflammatory profile, but 24 hours post-LPS treatment cytokine 
levels of TNFα, IL-1β, and IL-6 are similar to wild type. The concomitant decreased expression 
of the anti-inflammatory IL-10, another NF-κB target gene in macrophages, is unable to 
deactivate macrophages and inhibit inflammatory cytokine release. As described earlier, IL-10 is 
a critical signaling molecule for the resolution of inflammation. In addition, the p50 subunit of 
NF-κB can form homodimers in the nucleus to inhibit κB promoter elements (119).  
Other conflicting evidence exists for a role of NF-κB in atherosclerosis. Recently, an 
independent group showed that ablation of IKKβ in the bone marrow actually decreases 
atherosclerosis in Ldlr
-/-
 mice, even though IL-10 is similarly affected as previously described 
(267). Inhibition of NF-κB also results in decreased foam cell formation (267, 268). In the vessel 
wall, endothelium-specific inhibition of NF-κB through expression of a dominant-negative IκBα 
or deletion of IKKγ/NEMO protects Apoe-/- mice (269). Yet deletion of IκBα in the bone 
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marrow, investigated by the same group who deleted IKKβ in the macrophages above, 
aggravates atherosclerosis by enhancing leukocyte recruitment without affecting classical NF-κB 
genes (270). Clearly there is a complex and dual role for NF-κB in the control of inflammation. 
In addition to coordinating NF-κB signaling in macrophages (255) and endothelial cells 
(271), there is evidence that PKCζ also participates in vascular function. PKCζ promotes VSMC 
proliferation by a variety of stimuli including norepinephrine, angiotensin II, insulin growth 
factor, and PDGF (272-275). In polymorphonuclear leukocytes, PKCζ mediates integrin-
dependent adhesion and chemotaxis (276) and their adhesion to endothelium (275). Increased 
PKCζ activity is linked to athero-susceptibility in sites of disturbed flow in aortic endothelium 
(277). Moreover, inhibition of PKCζ by antisense oligonucleotides significantly decreases 
neointima formation in injured rat carotid arteries (278). 
 
1.3 THE SCAFFOLDING PROTEIN EBP50 
1.3.1 Discovery and Structure 
The discovery of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50), a scaffolding 
protein that assembles signal transduction complexes, was the product of two independent 
groups focused on different areas of inquiry. The origin of the name EBP50 evolved from a 
search for proteins bound to ezrin. Immobilized NH2-terminal fragments of ezrin and moesin 
revealed EBP50 as a binding partner (279). They also noticed that this protein migrated as 
multiple bands ranging from 50kDa to 53 kDa which were resolved into a single band of 50kDa 
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with phosphatase treatment, indicating phosphorylation (279). Concurrently, another group was 
pursuing a necessary regulatory cofactor of cAMP-mediated inhibition of Na
+
/H
+
 exchanger 
(NHE) activity in the renal brush border membrane (280, 281). This cofactor was a substrate for 
PKA phosphorylation distinct from the exchanger and coined Na+/H+ exchanger regulatory 
factor (NHERF)  (282).  These two terms for the same protein, EBP50 and NHERF1, are used 
interchangeably throughout the literature; in this text I will refer to the protein as EBP50.  
EBP50 is comprised of two tandem postsynaptic density 95/discs-large/zona occludens 
(PDZ) domains (termed PDZ1 and PDZ2) followed by a C-terminal ezrin-binding domain (EBD) 
(Fig. 1-5). This EBD serves to anchor binding partners of EBP50 to the underlying cytoskeleton. 
The most abundant protein-protein interaction module, PDZ domains are typically 80-100 amino 
acid residues in length and composed of six β-strands and two α-helices (283). The single 
carboxylate binding loop within each domain is highly conserved and features a core motif of G-
Ф-G-Ф, where the first glycine is permissive and Ф is a hydrophobic residue (GYGF in the case 
of EBP50) (284). The hydrophobic residues in this motif help form the hydrophobic ligand-
binding pocket (285). As its name suggests, the carboxylate binding loop recognizes defined 
sequences at the extreme C-terminus of target proteins (286), although binding to internal 
sequences has also been reported (287-290). PDZ domains can be classified based on the motifs 
with which they interact: class I prefers (E/D)-S/T-X-Ф, where X is any amino acid; class II 
recognizes Ф-X-Ф; and class III favors D/E-X-Ф (286, 291). However, upstream residues may 
also be important, especially in determining specificity for PDZ1 or PDZ2 (292). The PDZ 
domains in EBP50 are largely considered class I (293, 294), although they can interact with other 
motifs (295-298). Consequently, EBP50 terminates in a consensus PDZ motif (S-N-L) and can 
self-associate in an intramolecular head-to-tail interaction between PDZ2 and the EBD (299). 
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This closed conformation hinders interactions between PDZ domains and their ligands. Binding 
of the EBD to ezrin unmasks the PDZ domains and restores the ability of EBP50 to assemble 
complexes (299). 
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Figure 1-5: Structure of EBP50 
EBP50 is 358 amino acids in length and contains two tandem PDZ domains (blue boxes) followed by a C-terminal 
EBD (yellow circle). As a phosphoprotein, EBP50 is regulated by phosphorylation at multiple locations (red 
triangles). 
 
 
EBP50 is abundantly expressed in the apical membranes of polarized epithelial tissues 
including the kidney, small intestine, placenta, and liver (279, 300). Generally EBP50 
colocalizes with ezrin, particularly in the microvilli (279), but this is not absolute (301). 
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Additionally, EBP50 is present in airway epithelium, ependymal cells in the brain, mammary 
epithelium, and to a lesser extent in other tissues (279, 300, 302, 303). 
Additional related PDZ proteins have been discovered, mainly in epithelial tissues. 
NHERF2, shares 44% identity with EBP50 and a similar structure of two PDZ domains and a C-
terminal EBD (304). However, the distribution of these two family members is mutually 
exclusive (301). NHERF3 and NHERF4 are distinct from the former pair with four PDZ 
domains and no EBD (305-307).  
1.3.2 Regulation of EBP50 
1.3.2.1 Transcriptional 
Although other regulators have been discovered, estrogen is the main inducer of human EBP50 
expression. This regulation was first discovered using a differential RNA display to identify 
estrogen-responsive genes in breast cancer (300). Interestingly, the human SLC9A3R1 (EBP50) 
promoter lacks any palindromic full estrogen response elements (ERE) but instead contains 13 
half-ERE sites consisting of TGACC or GGTCA in the first 3.5 kilobases which are sufficient 
for estrogen receptor (ER) binding (308). Other estrogen-responsive genes such as ovalbumin 
can function without any accompanying complete palindromic ERE sites (309). In addition, 
SLC9A3R1 lacks a canonical CAAT or TAT box in the promoter region. These observations are 
consistent with studies showing a correlation between estrogen levels and EBP50 expression 
during the reproductive cycle (303, 310). EBP50 expression is also increased in ER+ breast 
cancer cells compared to ER- or normal mammary tissues (303, 311, 312). However, the mouse 
Slc9a3r1 promoter is deficient in ERE sites, full or otherwise, and thus is unresponsive to 
estrogen (313). Other hormones such as glucocorticoids, androgens, and progestin have no effect 
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on EBP50 expression (300). I will describe new advances in the transcriptional regulation of 
EBP50 stemming from my own work in a later section. 
1.3.2.2 Post-Translational 
The phosphoprotein EBP50 has 31 serine and 9 threonine residues available for post-
translational regulation. Depending on the residue, phosphorylation events can enhance or 
diminish EBP50 function. The phosphorylation sites described below are also depicted in Figure 
1-5.  
Although EBP50 does not contain a canonical PKA or PKC motif, there is evidence that 
these kinases lead to phosphorylation of EBP50. PKA does not phosphorylate EBP50 in vitro, 
but activation of the kinase using 8-bromo-cAMP induced phosphorylation of S77 (314). 
Therefore, additional signaling events may lie between PKA and EBP50 phosphorylation. 
In contrast, activators of the PKC pathway such as parathyroid hormone (PTH), 
dopamine, and 1,2-dioleoylglycerol, as well as direct in vitro kinase assays with PKC, result in 
S77 phosphorylation (314-316). Located in the PDZ1 domain, this phosphorylation attenuates 
the interaction of EBP50 with numerous binding partners (314, 315). PKC additionally 
phosphorylates EBP50 at S339/340 in the EBD, weakening the EBP50-ezrin interaction and 
redistributing EBP50 from the membrane to the cytoplasm without affecting ezrin localization 
(317-319). Consequently, this generates increased PDZ interactions, possibly by disrupting the 
closed conformation of EBP50 and exposing the PDZ2 domain. PKC also mediates the 
phosphorylation of S162, although the intramolecular interactions of the EBD and PDZ2 domain 
in the closed conformation may initially shield this residue (318). Furthermore, a triple PKC 
phosphomimic (S162/339/340D) increases EBP50 turnover on microvilli (319). 
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Other kinases that phosphorylate EBP50 include cyclin-dependent kinase 1 (Cdk1) and G 
protein-coupled receptor kinase 6A (GRK6A). GRK6A is responsible for the constitutive 
phosphorylation of rabbit EBP50 at S289 (S290 in humans). Interestingly, GRK6A terminates in 
a PDZ ligand (T-R-L) and interacts with EBP50, an event that is required for S289 
phosphorylation (320). This residue lies within a cluster of serines which are required for 
biological activity (321). EBP50 is highly phosphorylated during mitosis, more so than other 
stages of the cell cycle, due to the activity of Cdk1 (322). Cdk1 phosphorylates rabbit EBP50 at 
S279/301 (S280/302 in humans), an action that decreases microvilli formation (323). 
1.3.3 Physiology 
EBP50 currently has more known targets than any other PDZ protein (324). These targets 
include G protein-coupled receptors (GPCRs), ion transporters, receptor tyrosine kinases, and 
other non-receptor membrane and cytoplasmic signaling proteins. Some examples are outlined in 
Table 1. In this section I will describe some of the more prominent biological functions of 
EBP50, although there are clearly many more roles for this protein than summarized here. 
 
 
Table 1-1: Common PDZ ligands for EBP50 
Ligand PDZ-Binding Motif EBP50 PDZ Domain Reference 
GPCRs    
β2-Adrenergic Receptor DSLL 1 (325) 
Parathyroid Hormone Receptor 1 ETVM 1 (326) 
κ-Opioid Receptor NKPV 1 (296, 327) 
Ion Transporters    
NHE3 STHM 2 (328) 
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Cystic Fibrosis Transmembrane Regulator DSTL 1 > 2 (329, 330) 
Sodium-Phosphate Cotransporter Type IIa ATRL 1 (306) 
Receptor Tyrosine Kinases    
Epidermal Growth Factor Receptor DSFL (internal) 1 (331) 
Platelet-Derived Growth Factor Receptor DSFL 1 (332) 
Other    
β-catenin DTDL 2 (333) 
Phospholipase C β1 and 2 DTPL/ESRL 1 (334) 
Gqα YNLV 1/2 (335) 
 
1.3.3.1 Ion Homeostasis 
The EBP50 knockout mouse was originally generated by homologous recombination of 
exon 1 (336) and later using exons 1 to 4 (337), both cohorts reporting hypophosphatemia as a 
major phenotype. Mice genetically deficient in EBP50 exhibit normal blood chemistry except for 
a decrease in serum phosphate concentration (336). This is coupled to an increase in urinary 
phosphate and calcium excretion. Shenolikar et al. reported lower bone mineral density and an 
increased incidence of fractures (336), but this was not replicated in the mice generated by 
Morales and colleagues (337). The bone phenotype and calcium wasting was originally 
dismissed as secondary to the increased phosphate excretion since EBP50 is not expressed in the 
thick ascending limb or the distal convoluted tubule of the kidney where calcium is reabsorbed 
(338). However, recent studies demonstrate that EBP50 is required for osteoblast differentiation 
and matrix synthesis (339). 
Phosphate homeostasis, on the other hand, is primarily regulated in the proximal tubule 
by the sodium-phosphate cotransporter type IIa (Npt2a). EBP50 tethers this ion transporter to the 
apical membrane, facilitating phosphate reabsorption, and the absence of EBP50 results in the 
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redistribution of Npt2a to cytoplasmic vesicles (336). In contrast, EBP50 is also important for the 
PTH-mediated inhibition of Npt2a and phosphate transport. EBP50 stabilizes the parathyroid 
hormone receptor 1 (PTH1R) at the plasma membrane and PTH-induced phosphorylation at S77 
results in the disruption of the EBP50-Npt2a complex (314, 340, 341). Similarly, patients with 
SLC9A3R1 (EBP50) mutations (L110V, R153Q, E225K) present with phosphate wasting, kidney 
stones, and a history of bone fractures or low bone density (342). These mutations stabilize the 
closed formation of EBP50, impeding the formation of a ternary complex between EBP50, 
Npt2a, and ezrin and thus rendering the system refractory to phosphate reabsorption (343).  
True to its alternate name, EBP50 can also regulate Na
+
/H
+
 exchange via NHE3 binding. 
NHE3 is responsible for the majority of NaCl absorption in the intestine and kidney. While 
EBP50 does not affect the presence of NHE3 at the apical membrane, it is crucial for the cAMP-
PKA-mediated phosphorylation and subsequent inhibition of NHE3 activity (281, 336, 344, 
345). Furthermore, stimulation of the β2-adrenergic receptor (β2-AR) increases NHE3-mediated 
Na
+
/H
+
 exchange independently of G protein activation (346). This is thought to be due to the 
redistribution of EBP50 from NHE3 to β2-AR, releasing the inhibitory actions of EBP50 on 
NHE3. Physiologically, EBP50 is downregulated in intestinal biopsies from mouse models and 
patients with inflammatory bowel disease, resulting in diarrhea (347). 
A similar complex regulates the cystic fibrosis transmembrane regulator (CFTR) Cl
-
 
channel, although in a positive manner. In the absence of EBP50, HCO3
-
 is decreased in the 
duodenum (348). Additionally, stimulation of β2-AR with isoproterenol in human airway mucosa 
generates cAMP, activating CFTR-dependent chloride transport (349). Together EBP50, β2-AR, 
and CFTR exist in a PKA-dependent complex at the apical surface of both the small intestine and 
airway epithelium (348, 350, 351). EBP50 is vital for bringing CFTR in close proximity to β2-
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AR and the local concentrations of cAMP produced after stimulation (350). Additionally, about 
10% of CFTR mutations in cystic fibrosis are C-terminal deletions, and the lack of interaction 
with EBP50 interferes with proper CFTR distribution and Cl
-
 transport (352).  
1.3.3.2 Cancer 
There is no doubt that EBP50 plays a role in a number of different cancers, but whether it 
functions as a tumor suppressor (acting as a molecular brake on proliferation and migration) 
(353-356) or an oncogene (associated with metastasis and invasiveness) (311, 357-359) is 
controversial. In some reports, EBP50 is overexpressed in cancers of the breast, liver, and brain 
(311, 333, 358, 360). Not surprisingly, there is a strong correlation between EBP50 and ER 
status in ER+ breast cancers (303, 311, 312) and one study even discovered an upregulation of 
EBP50 after serum starvation and hypoxia, suggesting a positive association with the 
surrounding tumor environment (311). Conversely, screening of breast cancer cell lines and 
primary tumors reveals that a majority are undergoing loss of heterozygosity at the SLC9A3R1 
locus (17q25.1), some also with missense mutations (356). These genotypes are associated with 
higher aggressiveness and poor prognosis.  
In the instances where EBP50 is overexpressed in cancer tissues, there is a relocation of 
EBP50 from the membrane to the cytoplasm (303, 311, 312, 333, 361). Georgescu et al. 
proposed an elegant model which describes EBP50 as oncogenic when redistributed to the 
cytoplasm and a tumor suppressor when localized at the plasma membrane (362). Movement to 
the cytoplasm could disrupt protective complexes at the membrane and progress toward 
tumorigenic consequences. There are a number of mechanisms that support this theory. For 
instance, EBP50 can bridge phosphatase and tensin homolog (PTEN) to PDGFR in a ternary 
complex (363). PTEN is a tumor suppressor that dephosphorylates PIP3 to phosphatidylinositol 
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4,5-bisphosphate (PIP2), antagonizing PI3K activity (364). Complex assembly via EBP50 
suppresses PI3K activation in response to PDGF and slows down migration (363). Another 
example is the regulation of β-catenin by EBP50. At the membrane, β-catenin stabilizes adherens 
junctions but interacts with T-cell factor/lymphoid enhancing factor in the nucleus to promote 
proliferation (365). EBP50 stabilizes β-catenin at the membrane and the absence or 
overexpression (relocation) of EBP50 generates increased β-catenin transcriptional activity (333, 
354). Additionally, EBP50 mediates an association between the ERM protein merlin and the 
epidermal growth factor (EGF) receptor (EGFR) which inhibits the receptor’s signaling (366). 
Dissolution of these complexes removes the checks EBP50 provides and allows for prolonged 
and even uncontrollable signaling and growth. 
1.3.3.3 Vasculature 
Significant roles for EBP50 in the vasculature have emerged in recent years and the work 
in our lab has been instrumental in this regard. EBP50 is normally restricted to the endothelium 
with little or no expression in VSMC but is robustly expressed in the proliferative VSMC of the 
neointima following endothelial denudation in rat femoral arteries (367). Furthermore, we 
reported a modest increase in EBP50 expression following parathyroid hormone-related peptide 
(PTHrP) treatment in VSMC, although additional stimuli are surely responsible for its 
compelling upregulation in injured vessels. Using a similar model, EBP50-null mice exhibit a 
striking decrease in neointima formation after wire injury (368).  
We have identified the effect of EBP50 in two key characteristics of vascular remodeling, 
proliferation and migration. VSMC lacking EBP50 exhibit significantly decreased rates of these 
two characteristics (368, 369). Consistent with the variety of binding partners EBP50 boasts, 
there are at least two mechanisms behind its effects on proliferation. N-terminal fragments 
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(amino acids 1-36) of PTHrP, which is also increased after vascular injury, typically inhibit 
VSMC proliferation through a PTH1R-cAMP-dependent pathway (367, 370). However, the 
overexpression of EBP50 increases total and membrane expression of PTH1R and restores the 
receptor’s ability to produce calcium signals (367). This results in an overall attenuation of the 
anti-proliferative effect of PTHrP (367). In addition, EBP50 negatively regulates the expression 
of p21 (368). This cell-cycle inhibitor is degraded by Skp2, part of the Skp1/Cullin-1/F-box E3-
ligase complex (371), which also happens to interact with EBP50 (368). Active Akt increases the 
interaction between Skp2 and EBP50, resulting in increased expression and stability of Skp2 
(368). Ultimately, EBP50 is a positive and stimulus-independent regulator of VSMC 
proliferation. 
EBP50 also promotes the motility of VSMC (369). The non-receptor tyrosine kinase 
focal adhesion kinase (FAK) plays a central role in focal adhesion turnover and cell migration 
(372), a function that is newly dependent on EBP50. EBP50 bridges the interaction between 
EGFR and FAK, facilitating the phosphorylation of FAK after EGF treatment (369). Activation 
of FAK leads to increased focal adhesion turnover and migration, characteristics that are 
diminished in VSMC lacking EBP50 (369).  
Concurrently, the Morel lab at the  Catholique de Louvain in Belgium has also 
been looking into the functions of EBP50 in vasculature, albeit within the rat as opposed to the 
mouse. First, they demonstrate a noradrenaline-dependent interaction between EBP50 and 
moesin, leading to a decrease in the contractile response of mesenteric arteries (373). Second, 
Baeyens and colleagues propose that EBP50 acts as a molecular brake on migration. Curiously, 
knocking down EBP50 in rat VSMC results in a decrease in the number and size of focal 
adhesions and an overall faster migration rate, opposite of what we observe in mouse VSMC 
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(374). The authors conclude EBP50 inhibits the stable formation of microtubules through 
associations with myosin IIa, thus slowing down migration. In addition to the difference in 
species of VSMC utilized, these experiments were conducted in prolonged absence of serum, 
whereas we stimulated our cells with growth factors or maintained them in minimal serum 
conditions for no more than 16 hours. Therefore, the discrepancy in conditions may have led to 
differences in EBP50 phosphorylation and thus altered its functions. This could explain the 
differences in results seen between the two labs. 
The role of EBP50 in the endothelium has not been as thoroughly researched with only 
two publications on the topic to date. In contrast to VSMC, EBP50 has no effect on PDGF-
mediated proliferation or chemotaxis in porcine aortic endothelial cells (375). In a second study 
focused on the mitosis-specific phosphorylation of EBP50 in bovine pulmonary artery 
endothelial cells, overexpression of EBP50 has no effect on wound healing but a Cdk1 
phosphomimic mutant (S288/301D, 280/302 in humans) slightly accelerates the process (376). 
Interestingly, EBP50 is strictly nuclear in these endothelial cells and only shifts to the cytoplasm 
when it is phosphorylated during mitosis (376). It is possible that dephosphorylation of these 
sites is necessary for mitotic exit, and preliminary evidence suggests this may be mediated by 
PP2Ac (376). Certainly further studies need to be conducted on EBP50 in the endothelium. 
Although they do not always reside within the physical vessel wall, circulating 
leukocytes are important in the progression and resolution of vascular diseases. There is growing 
evidence that EBP50 helps guide important functions in macrophages and neutrophils. 
Phosphatidylinositol-phosphate kinase β (PIPKIβ) is required for dHL60 (a neutrophil-like cell 
line) cell polarity and chemotaxis, a function dependent on the C-terminal tail of the kinase 
(377). Consequently, EBP50 binds the C-terminus and links PIPKIβ to the cytoskeleton, 
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associations which are augmented in response to chemoattractants (377). EBP50 then localizes 
PIPKIβ to the uropod of the chemotaxing neutrophils to facilitate polarization and chemotaxis 
(378). EBP50 also scaffolds the interaction between CXCR2 and phospholipase C β (PLCβ) 2 in 
dHL60 cells (379). CXCR2, a Gi-coupled GPCR, is one of the main chemokine receptors in 
neutrophils mediating the chemotactic response to IL-8 (380-382). Calcium influx is additionally 
required for leukocyte migration and this is mediated by PLCβ2, the main PLC isoform in 
neutrophils (383, 384). When the CXCR2-EBP50-PLCβ2 complex is disrupted by a peptide 
corresponding to the PDZ motif of CXCR2, the release of calcium stores, migration, and 
endothelium infiltration are inhibited (379). Thus, EBP50 has multiple modes of controlling 
neutrophil chemotaxis. 
EBP50 is furthermore important in the bactericidal function of macrophages. iNOS 
generates high quantities of nitric oxide for host protection and proximity to the pathogen is 
imperative for its efficacy (385). EBP50 has previously been shown to bind iNOS in epithelial 
cells, and this interaction is essential for proper targeting of iNOS to phagosomes in RAW 264.7 
macrophages in response to LPS (386, 387). Remarkably, EBP50 expression is also increased 
after LPS treatment, a finding that may open new doors to explaining its upregulation after 
vascular injury (386). 
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1.4 RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS 
1.4.1 Rationale and Hypothesis 
CVD is the leading cause of death in developing countries. In fact, Americans have a 50% 
greater risk of dying from CVD than cancer (388). Atherosclerosis, an inflammatory disease, is a 
common precursor to ischemia and myocardial infarction. Even with the best current treatment 
the risk of another major adverse cardiovascular event is 70-80% (389). The vascular response to 
this inflammation requires communication between multiple cell types including VSMC and 
macrophages. Even though a number of signaling pathways have been implicated in vascular 
diseases, there still exist many gaps in this knowledge. Current studies in the laboratory have 
identified EBP50 as a key mediator of vascular remodeling (368). However, the function of 
EBP50 in inflammation and atherosclerosis has never been explored and my preliminary data 
suggest a role as an inflammatory mediator. Collectively, my studies suggest that EBP50 is 
involved in the pathogenesis of atherosclerosis. It is hypothesized that EBP50 is a central 
mediator of macrophage activation and the response of VSMC to inflammation. This novel 
mechanism may be an important cause of atherosclerosis and its elucidation has significant 
translation implications for the development and targeting of pharmacological therapies. 
1.4.2 Specific Aim 1: Explore the Role of NF-κB in the Regulation of EBP50 Expression 
Little is known about what regulates EBP50 expression in tissues besides estrogen. One study 
has demonstrated an upregulation of EBP50 upon LPS treatment in macrophages (386). This 
suggests that EBP50 is under control of NF-κB, an LPS-inducible pathway. Initial examination 
  46 
of the EBP50 promoter revealed multiple potential binding sites for NF-κB according to its 
consensus sequence GGGA/GNNC/TC/TCC, where N is any nucleotide (390). LPS and other 
inflammatory activators will be used to confirm the upregulation of EBP50 by NF-κB in VSMC 
and macrophages. Furthermore, pharmacological and molecular inhibitors of the NF-κB 
signaling pathway will be utilized to determine the importance and specificity of NF-κB on 
EBP50 expression. 
1.4.3 Specific Aim 2: Determine the Involvement of EBP50 in Potentiating NF-κB 
Activity 
Preliminary data indicated that EBP50 is necessary for iNOS expression following LPS 
treatment in VSMC. This suggests that EBP50 may be regulating the expression of iNOS and 
other NF-κB-inducible genes. EBP50 has already been shown to enhance NF-κB activity in 
stimulated bronchial epithelial cells (391).  The goal of this Aim is to define the molecular 
mechanism by which EBP50 regulates NF-κB. 
1.4.4 Specific Aim 3: Investigate the Effect of EBP50 on Macrophage Activation and 
Atherosclerosis in Ldlr
-/-
 Mice 
Previous data demonstrated that femoral arteries from EBP50-null mice exhibit decreased 
neointimal thickening after wire injury, an acute response to inflammation (368). It is therefore 
possible that EBP50 affects the activation of macrophages at the site of injury and thus the 
translation of inflammatory signals to VSMC. The goal of this Aim is to characterize the 
inflammatory environment in vivo and the activation of macrophages in vitro. In addition, the 
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contribution of EBP50 to a more chronic form of inflammation will be determined in atherogenic 
Ldlr
-/-
 mice. To this end, bone marrow from C57BL/6 or EBP50
-/-
 mice will be transplanted into 
Ldlr
-/- 
mice. Extensive analysis of inflammation and atherosclerotic burden in these mice will be 
performed following 12 weeks of high-fat/high-cholesterol diet. 
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2.0  EBP50 AND NF-ΚB: A FEED-FORWARD LOOP FOR VASCULAR 
INFLAMMATION 
The interaction between vascular cells and macrophages is critical during vascular remodeling. 
Here I report that the scaffolding protein, EBP50 is a central regulator of VSMC function. 
EBP50 is upregulated following endoluminal injury and promotes neointima formation. 
However, the mechanisms underlying these effects are not fully understood. Because of the 
fundamental role that inflammation plays in vascular diseases, I hypothesized that EBP50 
mediates the response of vessels to inflammation. Indeed, EBP50 expression increased in 
primary macrophages and VSMC, and in the aorta of mice, upon treatment with LPS or TNF . 
This increase was NF-κB-dependent. Conversely, activation of NF-κB was impaired in EBP50-
null VSMC. I found that inflammatory stimuli promote the formation of an EBP50-PKC  
complex at the cell membrane that induces NF-κB signaling. Vascular inflammation after acute 
LPS treatment was reduced in EBP50-null cells and mice compared to WT. Furthermore, 
macrophage recruitment to vascular lesions was significantly reduced in EBP50 knockout mice. 
Thus, EBP50 and NF-κB participate in a feed-forward loop leading to an enhanced response of 
VSMC to inflammation. 
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2.1 INTRODUCTION 
Inflammation is a necessary biological response to injury and infections. Yet, over-activation and 
chronic inflammatory status can lead to diseases such as cancer, asthma, rheumatoid arthritis, 
and cardiovascular disease. Over the past two decades the critical role of inflammation in the 
etiology of neointimal hyperplasia and atherosclerosis has emerged (3-6). Compelling evidence 
correlates risk factors for vascular disease (such as dyslipidemia, obesity, and hypertension) to 
inflammation (5, 392, 393). Moreover, a strong link between inflammation and the progression 
and adverse prognosis of atherosclerosis has been documented in humans (394, 395). Vascular 
inflammation is a major cause of the increased growth and migration of VSMC (396, 397) and 
for the expression of adhesion molecules (such ICAM-1 and VCAM-1) that are critical for the 
further recruitment of inflammatory cells to the lesion site (15). The local production of 
cytokines and growth factors stimulates phenotypic changes in VSMC leading to increased 
proliferation, motility, and matrix production ultimately resulting in plaque formation and 
neointimal hyperplasia. 
 Many of the genes implicated in vascular dysfunction are regulated by the transcription 
factor NF-κB (149, 257). NF-κB is rapidly induced by the cytokines IL-1β, TNFα, and infectious 
agents such as LPS. NF-κB is sequestered in the cytoplasm under basal conditions by IκBα 
(157). Activation of the IKK complex results in the phosphorylation and subsequent degradation 
of IκBα (163), allowing translocation of NF-κB into the nucleus. NF-κB activity is normally low 
in vessels but is rapidly activated during vascular injury. Degradation of IκBα and increased NF-
κB-dependent gene expression was observed after balloon injury (260). Similarly, administration 
of an IκBα adenovirus during angioplasty decreased ICAM-1 and MCP-1 expression as well as 
macrophage recruitment and lumen narrowing (261). 
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 The physical and functional interaction between vascular cells and macrophages is 
therefore critical during vascular remodeling and the identification of mediators of this 
interaction is significant for understanding the molecular mechanisms leading to vascular 
disease. Here we report that the PDZ-scaffolding protein EBP50 is a central mediator of this 
interaction. 
EBP50, also known as NHERF1, is a scaffolding protein that assembles signal 
transduction complexes through its two PDZ domains (279, 398). This adaptor protein also 
contains an EBD that tethers binding partners to the cytoskeleton. EBP50 is expressed at low 
levels in healthy vessels, but is significantly upregulated after endoluminal injury (367). EBP50 
increases VSMC proliferation and motility, and consequently neointima formation following 
wire injury is greatly reduced in EBP50 knockout (KO) mice (367-369). However, the molecular 
mediators that increase EBP50 expression in injured vessels are not known. Similarly, the effects 
of EBP50 on inflammation and on the response of vascular cells to inflammatory stimuli have 
not been established. In this study, we used a combination of in vitro and in vivo approaches to 
determine the mechanisms controlling EBP50 expression and the role of EBP50 on NF-κB 
signaling and inflammation. Our observations indicate that EBP50 and NF-κB participate in a 
feed-forward loop propagating vascular inflammation. 
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2.2 MATERIALS AND METHODS 
2.2.1 Plasmids and Mutagenesis 
The N-terminal Flag-tagged EBP50 mutants were constructed as previously described (369). The 
PKCζ-EESA mutant construct was made from wild-type PKCζ (a generous gift from Peter 
Parker, King’s College London) by using the QuikChange site-directed mutagenesis kit from 
Stratagene. Mutagenic primers were designed based on rat PKCζ sequence (5'-
GTCTGCTGAGGAGTCCGCGTGACTCTAGAG-3'). N-terminally CFP-tagged PKCζ was 
constructed by inserting WT PKCζ into a pcDNA3-CFP vector (Addgene plasmid #13030, a 
generous gift from Doug Golenbock). DNA sequences were confirmed by sequence analysis 
(GENEWIZ). 
2.2.2 Experimental Animals and Surgeries 
Animal surgeries were performed in 10-week old WT C57BL/6 mice and KO littermates. Mice 
were anesthetized using Ketamine (100 mg/kg) and Xylazine (5 mg/kg) i.m. A fixed core wire 
guide 0.015 inch (Cook Medical Incorporated) was inserted into the left femoral artery and 
passed within the artery 3 times. The right femoral artery was used as uninjured control artery. 
Femoral arteries were harvested 1 week post-surgery.  
 For the LPS studies, mice were injected with 10 mg/kg LPS i.p. for 16 h before sacrifice. 
The aorta and femoral arteries were harvested and analyzed as described later. All animal 
procedures were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee. 
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2.2.3 Cell Culture, Treatments, and Transfections 
To isolate peritoneal macrophages, mice were sacrificed by CO2 inhalation and cervical 
dislocation and warm RPMI media containing 10% FBS was injected into the abdominal cavity. 
After gentle shaking for 1-2 min, the lavage was collected and cells (3 x 10
6
) were plated in 6-
well plates and incubated at 37ºC for 2 hours (h). Cultures were vigorously washed with cold 
PBS to remove non-adherent cells. Macrophages were incubated overnight in 5% CO2 at 37ºC 
before treatment to allow for quiescence. Primary VSMC were isolated from abdominal aortic 
explants and grown in DMEM containing 10% FBS in 5% CO2 at 37ºC as previously described 
(369). All experiments were performed with cells between passages 5 and 15. Monolayers of 
clonal mouse RAW 264.7 macrophages (ATCC) were grown in DMEM containing 10% FBS.  
  p65-Flag (Addgene plasmid #20012, a generous gift from Dr. Stephen Smale) (399) and 
IκBα S32A/S34A (a generous gift from Dr. Lawrence Kane, University of Pittsburgh School of 
Medicine) were transfected in RAW 264.7 cells using HP XtremeGene (Roche) according to the 
manufacturer’s instructions and used for experiments 1-2 days later. Various constructs including 
pcDNA3.1, p65-Flag, PKCζ, PKCζ-EESA,  Flag-EBP50, Flag-EBP50-S1S2, and Flag-EBP50-
ΔEBD were introduced into VSMC by electroporation using an AMAXA electroporator and the 
Basic Nucleofect kit for primary smooth muscle cells (Lonza) as previously described (369). For 
expression of different PKCζ constructs, VSMC were infected with adenoviruses encoding LacZ, 
WT PKCζ, myristoylated (Myr) PKCζ (containing the NH2-terminal c-src myristoylation signal 
(400)), or kinase dead (KD) PKCζ (K281W), all generous gifts from Dr. Adolfo García-Ocaña 
(Mount Sinai Medical Center). Cells were incubated with adenovirus in serum-free media for 1 h 
and incubated with 10% FBS-supplemented media overnight. Experiments were performed at 48 
h after infection. Chinese hamster ovary (CHO) cells were cultured in Ham’s F-12 medium 
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supplemented with 10% FBS and transfected using X-tremeGENE HP (Roche) according to the 
manufacturer’s instructions. 
VSMC and macrophages were treated with 1 μg/ml and 100 ng/ml LPS (Sigma, catalog number 
L 4516, source Escherichia coli 0127:B8), respectively. Recombinant mouse TNFα (R&D 
Systems) was used at a concentration of 10 ng/ml for all cell treatments unless otherwise 
indicated. Cells were preincubated with inhibitors as indicated for 1 h, including 60 μM IKK 
Inhibitor II (Calbiochem) and 25 μM PKCζ psuedosubstrate (ζ-PS) (Calbiochem). VSMC were 
serum starved with 0.1% FBS in DMEM overnight prior to experiments. 
2.2.4 Nuclear Fractionation 
Pelleted VSMC were solubilized in cytoplasmic extract buffer (10 mM HEPES pH 7.9, 10 mM 
KCl, 0.1 mM EGTA pH 8, 0.1 mM EDTA pH 8, 0.5 mM DTT,) containing a protease inhibitor 
cocktail and placed on ice for 5 min. Lysates were centrifuged at maximum speed at 4°C for 5 
min to achieve separation of cytoplasm (supernatant) and nucleus (pellet). The nuclear pellet was 
briefly washed twice before resuspension in urea lysis buffer (see Immunoblot Analysis). 
2.2.5 Immunoblot Analysis 
Cells were solubilized in ice-cold lysis buffer (4 M urea, 62.5 mM TrisHCl, 2% SDS, 1 mM 
EDTA) containing a protease inhibitor cocktail. Proteins were resolved on a 10% SDS-PAGE gel 
and transferred to a nitrocellulose membrane. Blots were incubated with antibodies (1:500 
dilution for all except p65, Flag [both 1:1000], and actin [1:2000]) to EBP50, VCAM-1, IκBα, 
PKCζ (Santa Cruz), phospho-IKKα/β (S176/180), IKKβ, phospho-IκBα (S32), phospho-p65 
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(S536) (Cell Signaling Technology), p65, iNOS (BD Biosciences), β-actin, and Flag (Sigma) 
with secondary mouse or rabbit antibodies (Cell Signaling Technology, 1:2000 dilution). 
2.2.6 Co-Immunoprecipitation 
CHO cells were transfected as described above and treated with TNFα for 2 min before lysis in 
RIPA buffer (Santa Cruz). Equal amounts of protein were incubated with anti-PKCζ (1:500) for 
24 h at 4°C before 1 h incubation with Protein A/G beads (Santa Cruz). Samples were washed 
three times with cold NP-40 buffer (1 M Tris-base, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40) 
before elution with sample buffer and subsequent immunoblotting. 
2.2.7 Real-time RT-PCR 
RNA was isolated from cells and tissue using the RNeasy Mini Kit (Qiagen) and cDNA was 
generated using Im-Prom II Reverse Transcription System (Promega). Mouse primers to EBP50, 
VCAM-1, ICAM-1, IL-10, and GAPDH were designed using Primer 3 software and synthesized 
by Invitrogen. The specific primers were as follows: EBP50, forward 5’-
AGTGCAAAGTGATCCCATCC-3’, reverse 5’-GAGGGCTCTGTGGAAACTTG-3’; ICAM-1, 
forward 5’- CAGGCTGGAGATTGATCTG-3’, reverse 5’- 
GAGAGATGTAGAGTTGTAGTTC-3’; ICAM-1, forward 5’- 
GTGATGCTCAGGTATCCATC-3’, reverse  5’- GTCCACTCTCGAGCTCATC-3’; IL-10, 
forward 5’- AGCTGCGGACTGCCTTCAGC-3’, reverse 5’- ACAGCGCCTCAGCCGCATC-
3’; and GAPDH, forward 5’-CTCATGACCACAGTCCATGC-3’, reverse 5’- 
ATGTAGGCCATGAGGTCCAC-3. PCR reactions were run using the Power SYBR Green 
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(Applied Biosystems) reagent. The amplification program was as follows: 10 min at 95ºC, 40 
cycles of 15 seconds (s) at 95ºC, 30 s at 60ºC (or 55ºC for ICAM-1), and 60 s at 72ºC. A melting 
curve was run for 60 s at 60ºC and 15 s at 95ºC.  TaqMan primers to MCP-1, iNOS, and actin 
were purchased from Applied Biosystems. The amplification program was as follows: 20 s at 
90ºC, 40 cycles of 1 s at 90ºC and 20 s at 60ºC. 
2.2.8 Total Internal Reflection Fluorescence (TIRF) Microscopy 
CHO cells expressing CFP-PKCζ with or without YFP-EBP50 were analyzed by TIRF at room 
temperature. After a 5 min stabilization, 10 ng/ml TNFα was added and images were collected 
every 20 s for 20 min. YFP-EBP50 was used to determine which cells were positive or negative 
for EBP50. The translocation of CFP-PKCζ to the cell membrane was calculated as a slope = 
CFP fluorescence/time after TNFα stimulation. 
2.2.9 Immunofluorescence 
Femoral arteries were fixed with 4% paraformaldehyde and embedded in OCT Tissue-Tek 
(Sakura Finetek). Sections (10 μm) were incubated in boiled Tris-EDTA buffer (10 mM Tris-
base, 8 μM EDTA, 0.05% Tween-20) for 10 min, blocked in 4% NGS, 1% BSA, 0.5% Triton 
X100 for 20 min at room temperature and incubated with anti-CD68 (AbD Serotec, 1:100 
dilution), anti-VCAM-1 (Santa Cruz, 1:100 dilution), or anti-ICAM-1 (Santa Cruz, 1:100 
dilution). As a secondary antibody, anti-rabbit Alexa546-conjugated IgG (Invitrogen, 1:250 
dilution) was used before DAPI staining. Fluorescence intensities were measured with ImageJ 
software (National Institutes of Health). 
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2.2.10 Statistical Analyses 
Results from each experiment were averaged and expressed as mean ± standard error (SE). 
Results were analyzed by one-way ANOVA with Tukey’s test or Student’s t-test. P-values were 
considered statistically significant when lower than 0.05. 
 
2.3 RESULTS 
2.3.1 Inflammatory Cytokines Increase EBP50 Expression via NF-κB 
EBP50 expression increases after endoluminal arterial injury (367, 368), but the mechanisms 
controlling this upregulation are unknown. In the first series of experiments we tested whether 
inflammatory stimuli mediate EBP50 expression in VSMC and macrophages. Stimulation of 
primary peritoneal or RAW 264.7 macrophages and VSMC with LPS for 16 h resulted in a 
significant increase in EBP50 expression (Fig. 2-1A, C, D). Similarly, EBP50 mRNA expression 
in VSMC and RAW 264.7 increased with LPS and TNF  (Fig. 2-1B, E), indicating that the 
effect was not receptor specific and at the transcriptional level.  Additional experiments in mice 
treated with LPS confirmed that inflammatory stimuli increase EBP50 transcripts in the aorta 
(Fig. 2-1F). 
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Figure 2-1: Inflammatory stimuli increase EBP50 expression. 
A. Peritoneal macrophages were treated for 16 h with 100 ng/ml LPS and the protein extracts subjected to Western 
blotting for EBP50. B. RAW 264.7 cells were treated with or without 100 ng/ml LPS or 10 ng/ml TNFα for 16 h 
before isolating RNA. EBP50 RNA was analyzed by quantitative RT-PCR. C. RAW 264.7 cells were treated as in A 
and immunoblotted for EBP50. D. Primary VSMC were treated with 10 μg/ml LPS for 16 h. Cells were lysed and 
blotted for EBP50. E. Primary VSMC were treated with 10 ng/ml TNFα for 16 h. RNA was isolated and analyzed 
by quantitative RT-PCR. F. WT mice were injected with 10 mg/kg LPS for 16 h before sacrifice. RNA was 
extracted from the thoracic aorta and analyzed for EBP50 expression by RT-PCR. In all immunoblotting analyses β-
actin was used as a loading control; GAPDH was the control for RT-PCR. All data represent n > 3, mean ± SE; *, p 
< 0.05; **, p < 0.01. 
 
 
    LPS and TNF  signaling converge on the activation of NF-κB, suggesting that this 
transcription factor mediates EBP50 expression in inflammatory conditions. Analysis of the 
promoter region of Slc9a3r1 (EBP50) revealed multiple potential binding sites for NF-κB, 
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including two perfect matches (Table 2-1). Thus, it is possible that NF-κB binds to the Slc9a3r1 
promoter. 
 
 
Table 2-1: NF-kB consensus sites are present in the Slc9a3r1 promoter. 
NF-κB consensus motif: GGGA/GNNC/TC/TCC 
Promoter Region Sequence 
[-2515...-2506] GGGGAGCCCC 
[-2023…-2014] GAGAAATCCC 
[-1980…-1971] GAGAAATCCC 
[-484…-475] GGGGAATCGC 
[+136…+135] GGGCCGTCCC 
[+219…+228] GGGGCGCCCC 
 
 
 
 
We tested this hypothesis by pre-treating with the irreversible IKK Inhibitor II 
(wedelolactone) or transfecting with a dominant negative form of IκBα (S32A/S36A) that is 
unable to be phosphorylated and prevents NF-κB activation. We found that both IKK Inhibitor II 
and IkB (S32A/S36A) abrogated LPS-induced EBP50 expression in peritoneal macrophages 
(Fig. 2-2A) and RAW 264.7 cells (Fig. 2-2B). Conversely, over-expression of the p65 subunit of 
NF-κB, which overwhelms the basal inhibitory machinery and mimics activation, resulted in a 2-
fold increase in EBP50 expression (Fig. 2-2C). Comparable results were obtained in primary 
VSMC (Fig. 2-2D). These studies show that NF-κB regulates the expression of EBP50 in 
macrophages and VSMC under inflammatory conditions. 
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Figure 2-2: NF-κB regulates EBP50 expression. 
A. Peritoneal macrophages were treated with 60 μM IKK Inhibitor II (IKK I2) for 1 h prior to overnight stimulation 
with LPS. EBP50 expression was measured by Western blot. B. RAW 264.7 cells transfected with Flag-tagged 
dominant negative IκBα (S32A/S36A) were treated with LPS for 16 h. Extracts were subject to Western blotting for 
EBP50 and Flag. C. RAW 264.7 were transfected with vector (pcDNA3.1) or p65-Flag before lysing and blotting 
for EBP50 and Flag. D. VSMC were electroporated with vector or p65-Flag and expression of EBP50 and Flag was 
determined by immunoblot. In all immunoblotting analyses β-actin was used as a loading control. All data represent 
n > 3, mean ± SE; *, p < 0.05. 
 
2.3.2 EBP50 Promotes NF-κB Activation 
During the course of the previous studies, we made an unexpected observation. As described 
above, LPS stimulated EBP50 expression in VSMC from WT mice. This was accompanied by a 
parallel increase in iNOS expression (a bona fide NF-κB-responsive gene) (Fig. 2-3). As 
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expected, EBP50 was not detected in VSMC from KO mice. Consequently, LPS did not 
stimulate iNOS expression in these cells, suggesting that EBP50 regulates NF-κB signaling.  
 
 
iNOS
EBP50
WT KO
LPS (μg/ml):    0       1       10       0        1       10
β-actin  
Figure 2-3: iNOS is not induced in KO VSMC. 
WT and KO VSMC were treated with the indicated concentrations of LPS for 16 h before immunoblotting for iNOS 
and EBP50. β-actin was used as a loading control. 
 
 
Indeed, LPS-induced activation of IKK  was decreased in KO VSMC compared to WT VSMC 
(Fig. 2-4A). EBP50-null cells also exhibited decreased IκBα phosphorylation and degradation, 
and p65 phosphorylation at serine 536 (Fig. 2-4B). Importantly, LPS stimulated phosphorylation 
of p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun in both WT and KO VSMC 
(Fig. 2-4C), indicating that the effect of EBP50 on NF-κB signaling is specific and not related to 
defects in TLR4 signaling. Additionally, nuclear translocation of the p65 subunit is decreased in 
KO VSMC (Fig. 2-4D).  
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Figure 2-4: EBP50 increases NF-κB signaling. 
A, B, C. WT and KO VSMC were treated with 1 g/ml LPS for 0, 5, or 15 min. Lysates were analyzed by 
immunoblotting with the indicated antibodies. D. WT and KO VSMC were treated with 1 μg/ml LPS for 0, 30, or 
120 min. Cells were fractionated into cytoplasmic and nuclear extracts and analyzed by Western blot. In all 
immunoblotting analyses β-actin was used as a loading control.  
 
 
    To further explore the role of EBP50 in NF-κB activation, we performed a rescue 
experiment using KO VSMC. Introduction of EBP50 into these cells restored LPS-induced IKK 
phosphorylation (Fig. 2-5). EBP50 contains two PDZ domains, which are important for 
scaffolding binding partners, and a C-terminal EBD that interacts with cytoskeletal components. 
To identify the domains of EBP50 that are necessary for NF-κB activation we utilized EBP50 
constructs containing inactivating mutations in both PDZ domains (S1S2) or lacking the EBD 
domain (ΔEBD). Expression of either mutant was not sufficient to rescue IKK activation in KO 
VSMC (Fig. 2-5). 
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Figure 2-5: Rescue of the null phenotype with EBP50. 
KO VSMC were electroporated with the indicated Flag-tagged EBP50 constructs. After 24 h, cells were treated with 
or without LPS for 15 min and immunoblotted. Quantification is shown in the graph at right. In all immunoblotting 
analyses β-actin was used as a loading control. All data represent n > 3, mean ± SE; *, p < 0.05. 
 
2.3.3 EBP50 Interacts with PKCζ and Regulates NF-κB Activation 
The previous experiments show that the effect of EBP50 occurs upstream of the IKK complex. 
Examination of potential PDZ ligands in the C-termini of common components of TLR4- and 
TNF-R1-mediated signaling suggested PKC  as a potential target for EBP50. Indeed, PKC  
contains a typical type III consensus motif for PDZ binding (E-E-S-V) and participates in NF-κB 
activation by both LPS and TNF  (245, 246, 248). We determined the interaction between PKC  
and EBP50 in CHO cells that do not constitutively express EBP50. As shown in the co-
immunoprecipitation experiment in Figure 2-6A, TNF  promoted the association between PKC  
and EBP50. This was dependent on the PDZ-binding motif in PKC  because mutation of the C-
terminal valine to alanine abrogated the interaction with EBP50 (Fig. 2-6A).  
  We next determined the role of the interaction between EBP50 and PKC  on NF-κB 
activation. Consistent with previous reports (248, 255, 401), adenoviral expression of a kinase 
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dead PKC  (KD-PKCζ) or a PKC  pseudosubstrate inhibitor abrogated LPS-induced IKK 
phosphorylation in WT VSMC (Fig 2-6B, C). Conversely, adenoviral expression of a membrane-
targeted myristoylated PKC Myr-PKCζ) (242), but not of WT PKC , was sufficient to restore 
LPS-induced IKK phosphorylation in KO VSMC (Fig. 2-6D). These results suggested that 
EBP50 promotes membrane localization of PKC  in response to inflammatory stimuli. We 
therefore recorded PKC  translocation by TIRF microscopy.  TNF  stimulated CFP-PKC  
translocation only in CHO cells expressing EBP50 (Fig. 2-6E). This translocation began 
promptly after TNF  application and continued for at least 20 min. The slope of the membrane-
delimited CFP fluorescence over time after TNF  stimulation was significantly greater in 
EBP50-expressing cells than in naïve CHO cells (0.57±0.14 vs. 0.14±0.13 fluorescence·min
-1
 for 
EBP50 positive and negative cells, respectively; P = 0.031, n = 10) (Fig. 2-6F). Collectively, 
these experiments demonstrate that EBP50 potentiates NF-κB activity in response to 
inflammatory stimuli by a mechanism involving the formation of an EBP50-PKC  complex at 
the cell membrane. Interestingly, the PKC EESA mutant that does not interact with EBP50 
significantly inhibited LPS-induced IKK  phosphorylation (Fig. 2-6G), suggesting that this 
mutant functions as a partial dominant negative PKC  for NF-κB activation. 
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Figure 2-6: EBP50 interacts with PKCζ to promote NF-κB activation. 
A. CHO cells were transfected with vector (pcDNA3.1), WT PKCζ, or PKCζ-EESA mutant in conjunction with or 
without Flag-EBP50 as indicated and treated with TNFα for 2 min. Cell lysates were immunoprecipitated with anti-
PKCζ antibody. The immunoprecipitate (IP) and lysates (input) were immunoblotted as indicated. B. WT VSMC 
were infected with LacZ control or kinase-dead (KD) PKCζ (K281W) adenoviruses as indicated for 72 h before 
incubation with LPS for 15 min. Lysates were immunoblotted as shown. C. WT VSMC were pre-treated with 25 
μM PKCζ pseudosubstrate (ζ-PS) as indicated for 1 h before 15 min LPS treatment. Lysates were immunoblotted as 
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shown. D. KO VSMC were infected with LacZ control, WT PKCζ, or myristoylated (Myr) PKCζ adenoviruses for 
72 h before incubation with LPS for 0, 5, or 15 min as shown. Lysates were immunoblotted as shown. E. Time-
resolved changes in CFP fluorescence were measured using TIRF in single CHO cells expressing CFP-PKCζ with or 
without YFP-EBP50. Shown are the changes in membrane-delimited CFP fluorescence over 20 min after TNFα 
treatment. Error bars denote SEM (n = 10). F. Data were quantified as the slope of the CFP fluorescence over time 
during the first 5 min of TNFα treatment (n = 10). G. WT VSMC were electroporated with vector, WT PKCζ, or 
PKCζ-EESA as indicated. After 24 h, cells were treated with or without LPS for 15 min, lysed and immunoblotted 
as indicated. In all immunoblotting analyses β-actin was used as a loading control. All data represent n > 3, mean ± 
SE; *, p < 0.05.  
 
2.3.4 EBP50 Increases Inflammatory Responses in VSMC 
The expression of adhesion molecules by vascular cells in response to inflammation is critical for 
the homing of macrophages to lesion sites (17, 402). We therefore tested whether EBP50 
regulates the response of VSMC to inflammatory stimuli. We found that LPS-induced expression 
of the adhesion molecules ICAM-1 and VCAM-1, and of iNOS, were significantly reduced in 
KO VSMC compared to WT cells (Fig. 2-7A). In contrast, no differences in MCP-1 mRNA 
levels were observed. Similar observations were made upon treatment with TNF  (Fig. 2-7A), 
indicating that the effect of EBP50 is not receptor specific. The expression of VCAM-1 (Fig. 2-
7B), determined by immunoblotting, was also reduced in KO VSMC treated with TNF  for 16 
h. Thus, EBP50 promotes the response of VSMC to inflammatory stimuli. 
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Figure 2-7: EBP50 promotes adhesion molecule expression in VSMC. 
A. Primary WT and KO VSMC were treated with LPS or TNFα for 3 h. RNA was isolated and analyzed by 
quantitative RT-PCR with actin as the control. N.D., not detectable. B. WT and KO VSMC were treated with TNFα 
at the indicated concentrations for 16 h. Expression of VCAM-1 and EBP50 were determined by western blot and β-
actin served as the loading control. All data represent n > 3, mean ± SE; **, p < 0.01. 
 
2.3.5 EBP50 Increases Vascular Inflammation 
To determine the role for EBP50 on vascular inflammation in vivo we used two distinct 
experimental systems: an acute LPS-induced inflammatory model and an arterial injury model. 
In the first setting, WT and KO mice were injected with 10 mg/kg LPS for 16 h before excision 
of the femoral arteries. VCAM-1 and ICAM-1 expression was low in control (PBS injected) 
femoral arteries (data not shown). In WT mice, LPS induced robust expression of VCAM-1 in 
both endothelial and VSM cells, which was reduced by ~60% in KO mice (Fig. 2-8A). LPS-
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induced ICAM-1 expression occurred predominantly in the endothelium, and was also 
significantly reduced in KO mice (Fig. 2-8A).  
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Figure 2-8: EBP50 promotes vascular inflammation in vivo. 
A. WT and KO mice were injected with 10 mg/kg LPS for 16 h. Femoral arteries were excised and stained for 
VCAM-1 and ICAM-1 (in red). Nuclei were stained with DAPI (in blue).  Quantitation is shown at right as the mean 
± SEM; n = 4 (WT) and n = 3 (KO). B. Endoluminal denudation was performed in WT and KO mice. One week 
after surgery, injured and control femoral arteries were harvested and stained for the macrophage marker CD68 (in 
red). Nuclei were stained with DAPI (in blue) and autofluorescent elastin fibers are shown in green. * denote 
endothelial cells, ^ indicate positive CD68 staining. Quantification is shown as the mean CD68 fluorescence ± 
SEM;, n = 4 (WT) and n = 3 (KO). *, p < 0.05. 
 
  68 
To determine if EBP50 contributes to macrophage homing to sites of vascular injury, we 
performed endoluminal denudation in the femoral arteries of 10 week-old WT and KO male 
mice. One week after injury, macrophages in the lesion site were detected by CD68 staining. We 
chose this marker because its expression, determined by quantitative RT-PCR, is equivalent in 
primary WT and KO macrophages (data not shown). As shown in Figure 2-8B, abundant 
macrophages populated the intimal region of the injured vessel in WT mice. In contrast, we 
detected significantly fewer macrophages at the lesion site in KO mice. 
    Collectively, these experiments show that EBP50 increases the expression of adhesion 
molecules under inflammatory conditions and promotes the homing of macrophages to injured 
vessels. 
2.4 DISCUSSION 
In this study we show the reciprocal relationship between EBP50 and NF-κB, whereby NF-κB 
increases EBP50 expression under inflammatory conditions and EBP50 propagates NF-κB 
signaling. Consequently, EBP50 promotes the expression of adhesion molecules and macrophage 
recruitment at sites of vascular injury. A schematic representation of the action of EBP50 under 
inflammatory conditions is shown in Fig. 2-9. 
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Figure 2-9: Schematic representation of the effect of EBP50 under inflammatory conditions. 
In response to inflammatory stimuli, EBP50 recruits PKC  at the cell membrane and promotes IKKβ 
phosphorylation and activation of NF-κB. NF-κB induces expression of EBP50, inflammatory cytokines and 
adhesion molecules that further promote the inflammatory response. 
 
 
The upregulation of EBP50 has been reported in multiple disease states including 
hepatocellular carcinomas, cholangiopathies, glioblastoma, breast cancer, psoriasis, and vascular 
injury (311, 312, 333, 358, 368, 403, 404). However, little is known on the transcriptional 
regulation of EBP50 expression in normal and disease states. Estrogen is the best characterized 
inducer of EBP50 expression (300, 303, 308) but murine EBP50 is unresponsive to estrogen 
(313). We reported an increase in EBP50 expression in VSMC overexpressing PTHrP (367), yet 
this modest 50% increase does not account for the remarkable EBP50 upregulation upon 
vascular injury in rodents (367, 368). Confirming an earlier report from Davis and colleagues 
(386), we observed a significant increase in EBP50 expression upon treatment with either LPS or 
TNFα in macrophages and VSMC. Furthermore, we found that this effect was transcriptional and 
fully dependent on NF-κB activity. Although not yet proven, the presence of two perfect NF-κB 
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consensus motifs and multiple other similar sequences in the Slc9a3r1 promoter opens up the 
possibility of a direct interaction between the two components. The regulation of EBP50 by NF-
κB is relevant in animal models of vascular injury: NF-κB activity is normally low in uninjured 
arteries but IκBα degradation and upregulation of NF-κB-responsive genes (such as VCAM-1) 
are observed upon angioplasty (260). We recently reported that EBP50 expression is low in 
normal vessels and increases following endoluminal denudation in rat and mouse arteries (367, 
368). Thus, both NF-κB activity and EBP50 expression increase during vascular remodeling and 
our studies provide a mechanistic basis for these effects. 
Interestingly, we found that EBP50-null VSMC were impaired in their ability to activate 
NF-κB in response to inflammatory stimuli. This is consistent with a report from Estell et al. 
showing that NF-κB binding to DNA in bronchial epithelial cells was dependent on EBP50 
(391). In our studies, the reduction in IKK phosphorylation in EBP50-null cells indicates that 
EBP50 exerts its effects early in the activation of NF-κB, upstream of the IKK complex. 
Moreover, the effect of EBP50 is not receptor-specific because it is observed with both LPS and 
TNF . We reasoned that a common effector of TLR4 and TNF-R1 could be the site of action of 
EBP50, and focused on PKC  because it possesses a C-terminal PDZ-binding motif and is 
essential for NF-κB activation. Indeed, our experiments show that inflammatory stimuli induce 
the formation of an EBP50-PKC  complex at the cell membrane. The magnitude of this effect is 
consistent with that observed in opossum kidney cells in response to dopamine (405). PKC  
translocation to the membrane appears to be the critical step for EBP50 action, because NF-κB 
activity in EBP50-null cells was rescued by a membrane-targeted myristoylated form of PKC  
but not by overexpression of WT PKC . Consistent with this mechanism, we found that at least a 
functional PDZ domain and the EBD in EBP50 are required for cytokine-induced IKK 
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phosphorylation. Therefore, both the ability to bind PKC  and to interact with the cytoskeleton is 
crucial for the effect of EBP50 on NF-κB activation. 
The regulation of NF-κB signaling by EBP50 has important consequences in 
inflammatory states. Expression of the adhesion molecules ICAM-1 and VCAM-1 (and of iNOS) 
was decreased in EBP50-null VSMC and mice. Consequently, homing of macrophages to the 
site of arterial injury was significantly reduced in KO mice. These observations provide further 
insight into the critical role of EBP50 during vascular remodeling. As we previously reported, 
EBP50 potentiates VSMC proliferation and motility (367-369). Here we show that EBP50 
regulates the response of VSMC to inflammatory stimuli and the recruitment of macrophages to 
injured vessels. Therefore, EBP50 promotes multiple critical events leading to aberrant vascular 
remodeling and genetic ablation of EBP50 confers remarkable protection from injury-induced 
restenosis. 
In summary, we have identified EBP50 as a positive regulator of NF-κB activation. 
Conversely, we have also demonstrated a role for NF-κB in the upregulation of EBP50 
expression. We propose that NF-κB and EBP50 participate in a positive feed-forward loop 
leading to enhanced responses of vascular cells to inflammation. 
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3.0  EBP50 ENHANCES MACROPHAGE ACTIVATION AND ATHEROSCLEROSIS 
Macrophages and other leukocytes are major players in the progression of atherosclerosis and 
other inflammatory diseases. Here we demonstrate a role for the PDZ scaffolding protein EBP50 
in macrophage activation. I have previously reported that EBP50 is a positive regulator of NF-κB 
activation and inflammatory responses in VSMC and wanted to extend these findings to 
macrophages. Additionally, I know that EBP50 can diminish vascular reactions to acute 
inflammation but its effect on chronic diseases such as atherosclerosis is unknown. Given these 
earlier findings, I hypothesized that EBP50 similarly promotes macrophage activation and 
atherosclerosis. Indeed, KO macrophages display diminished NF-κB signaling and subsequently 
decreased expression of pro-inflammatory cytokines when treated with LPS. To determine the 
myeloid-specific role of EBP50 in chronic inflammation, I performed transplants of WT or KO 
bone marrow into Ldlr
-/-
 mice. After placing these mice on a high cholesterol diet for 12 weeks, I 
observed no changes in glucose or lipid levels in the plasma. However, lesion sizes throughout 
the aorta were significantly decreased in mice receiving KO marrow. These data demonstrate 
that EBP50 in myeloid cells is important for the progression of atherosclerosis. Further 
examination of plaque composition will yield additional insight into this mechanism. 
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3.1 INTRODUCTION 
Atherosclerosis is considered a chronic inflammatory disease within the vessel wall, 
characterized by lipid-laden plaques with a fibrous coating (3-5). Elevated levels of lipids such 
as LDL in the blood trigger a weakness in the integrity of the endothelium. Monocytes are 
recruited to the site where they burrow into the intimal layer and start engulfing the lipids. These 
foam cells contribute to the local inflammatory environment and the formation of the necrotic 
core. Meanwhile, VSMC are stimulated to proliferate and migrate around the plaque to protect 
the lumen from the pro-thrombotic interior. VSMC additionally secrete extracellular matrix 
components such as collagen to aid in the construction of the fibrous cap. However, 
macrophages can also secrete MMPs which, while beneficial for the migration of VSMC, 
contribute to the thinning of the fibrous cap. It is clear that leukocytes are a major driver in the 
progression of this disease. 
 NF-κB plays a significant role in the development of atherosclerosis. Many initiating 
factors of this disease can activate NF-κB, including hypoxia, metabolic factors, infectious 
agents, T-cell activation, and cytokines (257). Activated NF-κB is present in endothelial cells, 
VSMC, and macrophages within the atherosclerotic plaque (262). NF-κB can induce the 
expression of over 150 genes, many of which are implicated in the pathogenesis of 
atherosclerosis including cytokines, adhesion molecules, MMPs, tissue factor, and anti-apoptotic 
proteins (149). Broad inhibition of NF-κB has been associated with decreased atherosclerosis 
(128, 264, 265) while other inhibitions of the pathway have had controversial effects. 
Macrophage-specific deletion of IKKβ surprisingly enhanced atherosclerosis in Ldlr-/- mice due 
to decreased levels of IL-10 and a defective resolution of inflammation (266). However, another 
group conversely found a decrease in atherosclerosis in Ldlr
-/-
 mice with IKKβ-/- bone marrow 
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(267). Additionally, endothelial-restricted expression of a dominant-negative IκBα or deletion of 
IKKγ/NEMO protected Apoe-/- mice from atherosclerosis (269). Certainly NF-κB directs 
complex functions in the control of inflammation. 
Recently, we discovered a role for EBP50 in vascular inflammation. EBP50, also known 
as NHERF1, is an adaptor protein that uses its tandem PDZ domains to assemble signal 
transduction complexes (279, 398). This scaffolding protein also contains an ezrin-binding 
domain at its C-terminus to tether ligands to the cytoskeleton. Normal vessels express low 
amounts of EBP50, which is significantly upregulated after arterial wire injury (367). EBP50 
positively regulates VSMC proliferation and migration and consequently is necessary for 
neointima formation (367-369). In addition, inflammatory stimuli and NF-κB control EBP50 
expression. Conversely, EBP50 potentiates NF-κB activation and the expression of its adhesion 
molecules in VSMC. 
While EBP50 is important for acute stimuli such as wire injury and LPS insult, it is 
unknown if this scaffolding protein has an effect on chronic inflammatory diseases such as 
atherosclerosis. In addition, macrophage activation in an EBP50-null setting has not yet been 
determined. In this report, we investigate the extent of macrophage activation in KO 
macrophages and utilize bone marrow transplants (BMT) to explore the leukocyte-specific role 
of EBP50 in Ldlr
-/-
 mice fed a diet high in cholesterol.  
 
3.1.1 Mouse Models of Atherosclerosis 
Several transgenic mouse strains have been generated that develop atherosclerotic lesions. Mice 
are typically put on a modified or “Western” diet enriched in fat, cholesterol, and cholate to 
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induce lesion formation. Inbred strains can also develop diet-induced atherosclerosis (C57BL/6 
are the most sensitive) but lesions generally remain small and fail to progress beyond the fatty 
streak (406). Apoe
-/-
 and Ldlr
-/-
 mice on a C57BL/6 background are the most commonly used to 
model this disease. ApoE is an important mediator of lipid metabolism, facilitating high-affinity 
binding of cholesterol to liver LDLR for uptake and degradation (407). Apoe
-/- 
mice are 
hyperlipidemic and can spontaneously develop atherosclerosis, even when fed a normal diet 
(408). Conversely, Ldlr
-/-
 do not develop lesions unless fed a modified diet (409). Both models 
display similar degrees of diet-induced atherosclerosis, although Apoe
-/-
 mice have higher 
cholesterol levels (410).  
Genetic combination of these models with other transgenics is an important tool to 
explore the function of a gene of interest in atherosclerosis. In addition, bone marrow transplants 
into atherosclerotic strains are an attractive way to investigate the specific effect of genetically-
modified hematopoietic cells (i.e. leukocytes, lymphocytes) on atherosclerosis. However, care 
must be taken as to whether the donor mice must first be back-bred onto the Apoe
-/-
 or Ldlr
-/-
 
background. Bone marrow transplantation of Apoe
+/+
 into Apoe
-/-
 mice can reduce cholesterol 
levels and cause a regression in atherosclerosis (411, 412). ApoE is synthesized by monocytes 
and its expression on these cells is sufficient to rescue the ApoE-null phenotype of 
hypercholesterolemia. However, extrahepatic LDLR has no effect on cholesterol or lesion 
development (413, 414). Therefore, it is necessary to genetically cross donor mice with Apoe
-/-
 
mice, but not Ldlr
-/-
 mice, before transplanting bone marrow into the respective atherosclerotic 
model. For this reason, we chose the Ldlr
-/-
 mouse as the model for our bone marrow transplant 
study. 
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3.2 MATERIALS AND METHODS 
3.2.1 Mice 
Homozygous male Ldlr
-/-
 mice were obtained from The Jackson Laboratory (Bar Harbor, ME) 
and housed in sterile, filter-top cages. For analysis of atherosclerosis, animals were fed an 
atherogenic diet with 1.25% cholesterol and 0.5% cholate (TD.02028, Harlan Laboratories) for 
12 weeks. All animal procedures were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
For the LPS studies, mice were injected with 10 mg/kg LPS i.p. for the indicated times 
before sacrifice. Blood was collected by cardiac puncture and the serum was used in a TNFα 
ELISA (R&D Systems) according to the manufacturer’s instructions. 
3.2.2 Bone Marrow Transplantation 
One day prior to transplantation, recipient Ldlr
-/-
 mice (10 weeks old) were subject to total body 
irradiation (9.5 Gy). The next day, the same mice received 7.5 x 10
6
 bone marrow cells through 
tail vein injection. Donor bone marrow was harvested by flushing the femurs of 8-10 week old 
male donor WT C57BL/6 mice or KO mice with RPMI 1640 containing 2% FBS, 10 U/ml 
heparin, and penicillin/streptomycin. Cells were washed twice with RPMI plus 20 mM HEPES 
and penicillin/streptomycin before injection. Sterile drinking water contained 0.672 mg/ml 
Sulfatrim for two weeks post-transplantation. Mice were put on the atherogenic diet four week 
post-transplantation for 12 weeks. 
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3.2.3 Blood Analysis 
Blood samples (50 μl) were obtained by tail bleeding four weeks post-transplantation to assess 
bone marrow reconstitution. Complete blood count was analyzed on a HEMAvet 950 (Drew 
Scientific). At the conclusion of the 12-week atherogenic diet, blood was drawn after an 
overnight fast and plasma cholesterol and triglyceride concentrations determined by enzymatic 
assays (BioAssay Systems). Glucose was measured using ACCU-CHEK Aviva test strips and 
blood glucose meter. For genotyping purposes, DNA was extracted from the blood using the 
QIAamp DNA blood mini kit (Qiagen). The primers used were 5’- 
TTCGGCCTCATTCTGGTC-3’ (common), 5’-GAGAAGGGTCCAAATGGCTA-3’ (WT 
forward), and 5’-CGCCTTCTTGACGAGTTCTT-3’ (mutant forward). 
 
3.2.4 Atherosclerotic Lesion Measurement 
After 12 weeks, mice were sacrificed and perfused with 4% paraformaldehyde. Aortas were 
dissected and stained en face with Oil Red O (Sigma). Briefly, aortas were washed in 60% 
isopropanol for 2 min, stained with Oil Red O for 18-20 min, then washed in isopropanol 
followed by PBS rinses. For lesion analysis, full-length aortas were embedded in OCT Tissue-
Tek (Sakura Finetek), divided into four sections per block (Fig. 3-1), and sectioned at 10 μm 
intervals. Sections spaced 300 μm apart were similarly stained with Oil Red O and Harris 
hematoxylin to calculate mean lesion area. 
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3.2.5 Cell Culture and Treatments 
Peritoneal macrophages were isolated from the peritoneum as described in section 2.2.3. These 
cells were briefly cultured in RPMI medium containing FBS and penicillin/streptomycin. 
Monolayers of clonal mouse RAW 264.7 macrophages (ATCC) were grown in DMEM 
containing 10% FBS. All macrophages were treated with 100 ng/ml LPS (Sigma) as indicated. 
Small interfering RNA (siRNA) for EBP50 knockdown was generated by Dhamarcon 
(Thermo Scientific) as follows: 5′-GAAGGAGAGCAGCCGUGAAdTdT3′ (sense) and 5′-
UUCACGGCUGCUCUCCUUCdTdT-3′ (antisense). As a control siRNA, Accell Non-targeting 
siRNA (Dharmacon, Thermo Scientific) was used. RAW 264.7 cells were plated onto 6-well 
plates and transfected with siEBP50 or control siRNA using RNAimax (Invitrogen Life 
Technologies) in DMEM with 1% FBS in the absence of antibiotics. Cells were transfected a 
second time the next day and used 48 hours after the last transfection. 
3.2.6 Immunoblotting 
Cells were solubilized in ice-cold lysis buffer (4 M urea, 62.5 mM TrisHCl, 2% SDS, 1 mM 
EDTA). Proteins were resolved on a 10% SDS-PAGE gel and transferred to a nitrocellulose 
membrane. Blots were incubated with antibodies to EBP50 (Santa Cruz, 1:500 dilution), F4/80 
(Abcam, 1:500), IL-1β (Abcam, 1:1000), and β-actin (Sigma, 1:2000) with secondary mouse or 
rabbit antibodies (Cell Signaling Technology, 1:2000). 
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3.2.7 Real-time RT-PCR 
RNA was isolated from cells and tissue using the RNeasy Mini Kit (Qiagen) and cDNA was 
generated using Im-Prom II Reverse Transcription System (Promega). TaqMan primers to TNFα, 
IL-1β, IL-6, iNOS, and actin were purchased from Applied Biosystems. The amplification 
program was as follows: 20 s at 90ºC, 40 cycles of 1 s at 90ºC and 20 s at 60ºC. 
3.2.8 Statistical Analyses 
Results from each experiment were averaged and expressed as mean ± standard error (SE). 
Results were analyzed by Student’s t-test. P-values were considered statistically significant when 
lower than 0.05. 
 
3.3 RESULTS 
3.3.1 Classical Macrophage Activation is Decreased in EBP50 KO Macrophages. 
Macrophage activity and the secretion of cytokines are important factors for the induction of 
proliferation, migration, and adhesion molecule expression in VSMC during vascular remodeling 
(6). Many of these cytokines are regulated by NF-κB, and since we have demonstrated the 
importance of EBP50 in the activation of this pathway in VSMC, we next sought to determine 
the effect of macrophage activation. To this end, we treated peritoneal macrophages isolated 
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from WT and KO mice with LPS for 3 h and assessed expression of pro-inflammatory mediators 
by quantitative RT-PCR. We found that the induction of IL-1β, iNOS, and TNFα was 
significantly decreased in KO macrophages compared to WT (Fig. 3-1A). In contrast, we 
observed no differences for IL-6 and IL-10. We then assessed macrophage activation in WT and 
KO mice treated with 10 mg/kg LPS for 2 or 16 h. Serum TNFα concentrations and the 
expression of IL-1β in macrophages were both significantly decreased in KO compared to WT 
mice (Fig. 3-1B, C). These experiments show that EBP50 increases macrophage activation and 
the production of inflammatory cytokines both in vitro and in vivo. 
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Figure 3-1: EBP50 promotes inflammatory cytokine production. 
A. WT and KO peritoneal macrophages were treated with LPS for 3 h before isolating RNA. RNA was analyzed by 
quantitative RT-PCR. N.D., not detectable.  B. WT and KO mice were injected with 10 mg/kg LPS (i.p.) and 
sacrificed after 2 h. Serum TNFα was determined by ELISA. n = 3 (WT) and 5 (KO).  C. WT and KO mice were 
injected with 10 mg/kg LPS and sacrificed 16 h later. Peritoneal macrophages were harvested and purified through 
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adhesion to culture dishes. After 2 h, cells were collected and expression of EBP50 and IL-1β determined by 
western blot. Immunoblotting for F4/80, a macrophage marker, verified the equal population of macrophages in 
each sample. In all immunoblotting analyses β-actin was used as a loading control; Actin was the control for RT-
PCR. All data represent n > 3, mean ± SE; *, p < 0.05; **, p < 0.01. 
 
 
In Chapter 2, we showed that EBP50 is a positive regulator of NF-κB activity in VSMC. 
Since Figure 3-1 demonstrated a decrease in classical NF-κB genes in KO macrophages, we 
hypothesized that EBP50 was also integrated into the NF-κB pathway in these cells. Treatment 
of RAW 264.7 macrophages with siRNA to EBP50 resulted in >80% knockdown (Fig. 3-2A). 
Indeed, siEBP50 macrophages displayed a lack of IκBα degradation and decreased p65 
phosphorylation (Fig.3-2B), confirming a function for EBP50 in macrophage NF-κB signaling. 
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Figure 3-2: NF-κB signaling is regulated by EBP50 in macrophages. 
A. RAW 264.7 cells were subjected to scrambled siRNA (siCtrl) or siEBP50 in a two-day transfection and used 24-
48 hours after the second transfection. This resulted in an approximately 80% knockdown of EBP50. B. RAW 264.7 
cells transfected with either siCtrl or siEBP50 were treated with LPS for 0, 5, or 15 min. Protein extracts were 
subjected to immunoblot as shown. β-actin was the loading control. 
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3.3.2 Deletion of EBP50 in Bone Marrow Does Not Affect Chimerism, Blood Cell Profile, 
or Lipid Parameters 
Since EBP50-null macrophages exhibit decreased activation, we wanted to investigate the role of 
these macrophages in a chronic vascular inflammatory state. Bone marrow from WT C57BL/6 or 
KO mice was transplanted into lethally irradiated Ldlr
-/- 
recipient mice to investigate the specific 
effects of EBP50 in macrophages and other myeloid cells on atherosclerosis. After four weeks 
recovery, blood was collected and analyzed for chimerism and successful engraftment. RT-PCR 
on blood cells confirmed the presence of only donor WT or KO marrow (Fig. 3-3A). A complete 
blood count demonstrated that white blood cell, lymphocyte, red blood cell, and platelet counts 
were within the normal murine ranges and not different between groups (Table 3-1).  
 
 
Table 3-1: Complete Blood Counts in Ldlr
-/-
 mice four weeks post BMT. 
Mice WT BMT KO BMT 
Red Blood Cells (M/μl) 8.6 ± 0.4 9.9 ± 0.1 
White Blood Cells (K/μl) 12.8 ± 1.3 14.2 ± 2.0 
Hemoglobin (g/dl) 12.1 ± 0.6 13.8 ± 0.2 
Platelets (K/μl) 599.7 ± 73 592 ± 92 
Neutrophils (K/μl) 2.6 ± 0.4 2.7 ± 0.4 
Eosinophils (K/μl) 0.2 ± 0.08 0.09 ± 0.03 
Basophils (K/μl) 0.07 ± 0.03 0.2 ± 0.01 
Monocytes (K/μl) 0.4 ± 0.07 0.4 ± 0.7 
Lymphocytes (K/μl) 9.5 ± 0.8 11.0 ± 1.6 
Values are mean ± SE. M, million; K, thousand. N = 8 (WT), 4 (KO). 
 
 
At this time, mice were put on a high-cholesterol diet for 12 weeks. Plasma glucose, total 
cholesterol, and triglyceride levels were similar between WT and KO recipients at the end of the 
diet (Table 3-2). Weight was also not different between groups. 
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Table 3-2: Body Weight and Plasma Glucose and Lipid Levels. 
  WT BMT KO BMT p (n, n) 
Weight (g) 23.4 ± 0.43 22.0 ± 0.52 0.380 (8, 7) 
Glucose (mg/dL) 92.2 ± 6.7 95.6 ± 5.6 0.707 (5, 5) 
Cholesterol (mg/dL) 1185.6 ± 89.6  1004.8 ± 102.5  0.21 (7, 7) 
Triglyceride (mg/dL) 155.2 ± 26.6 91.8 ± 14.7 0.0592 (7, 7) 
Values are mean ± SE and (n,n) denotes number of animals for (WT, KO)  recipient analysis after 12 weeks of high-
cholesterol diet 
 
 
Additionally, peritoneal macrophages were extracted to confirm proper chimerism (Fig. 3-3B). 
Animals that were transplanted with KO donor marrow did not express EBP50 in the 
macrophages as expected. 
 
 
EBP50
EBP50 Donor:
F4/80
β-actin
- - - - +       - +      +      +          +       +       +      +       - -
EBP50 Donor:   - - - Het Het
controls
A.
B.
 
Figure 3-3: Chimerism of Ldlr
-/-
 transplanted with indicated donor marrow. 
A.  Genotyping from the blood of three representative KO recipients confirms the absence of EBP50. Het controls 
were also run for proper band identification. The upper band signifies a WT while the lower band denotes KO. B. 
Peritoneal macrophages were extracted from Ldlr
-/-
 mice at the conclusion of the experiment and analyzed for proper 
EBP50 expression with Western blot. F4/80 established equal amounts of macrophages in the lysate and β-actin was 
used as a loading control. 
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Collectively, these studies confirm the complete ablation and reconstitution of bone marrow 
from the donor mice. Additionally, they show that EBP50 has no effect on hematopoiesis and 
myeloid cell lineage specification. 
3.3.3 EBP50-Null Myeloid Cells Decrease Lesion Size 
After 12 weeks of a high-cholesterol diet, aortas were analyzed for atherosclerosis severity. 
Surprisingly, en face Oil Red O staining showed a significant increase of percent lesion area 
covering the aorta in KO
  Ldlr-/- (KO BMT) compared to WT  Ldlr-/- (WT BMT) (Fig. 3-
4A). While both groups had lesions concentrated in the aortic arch, the KO BMT cohort had an 
additional cluster where the diaphragm divides the thoracic from the abdominal aorta. However, 
examination of sectioned plaques stained with Oil Red O revealed a significant 25% decrease in 
KO BMT cross-sectional lesion size throughout the aorta compared to the control (Fig. 3-4B).  
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Figure 3-4: KO BMT lesions are larger in aortic surface area but smaller in cross section. 
A, En face analysis of aorta after Oil Red O staining. The percent area of the aorta covered by lesions is graphed at 
right. N = 3 for both cohorts. B. , Cross-sectional area of lesions in the whole aorta after Oil Red O staining. 
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Quantification is at right. Data represent the mean ± SEM (* P < 0.05); n = 4 (WT BMT), 5 (KO
 
BMT) unless 
otherwise noted. 
 
3.4 DISCUSSION 
In this study we demonstrate a role for EBP50 in multiple phenotypes of macrophage activation 
and a decrease in atherosclerosis in mice with bone marrow lacking EBP50. Additionally, 
EBP50 regulates NF-κB activity, confirming what we previously found in VSMC. 
 We show that the expressions of IL-1β and TNFα, as well as iNOS, are decreased in KO 
macrophages in vitro and in vivo. In contrast, there was no effect on IL-6 or IL-10. IL-10 is an 
anti-inflammatory cytokine that can inhibit NF-κB activation, enhance macrophage 
efferocytosis, and promote the conversion of M1 pro-inflammatory macrophages to a regulatory 
phenotype (65, 415-417). An overall decrease in pro-inflammatory cytokines and a lack of effect 
on IL-10 suggests that the balance between pro- and anti-inflammatory events could be altered in 
the absence of EBP50, leading to a more efficient resolution of inflammation.  
 Recent reports highlight the emerging role for EBP50 in leukocyte function. Manes et al. 
showed that the interaction between EBP50 and PIP5KIβ is necessary for chemoattractant-
induced neutrophil polarization (378). Wu and colleagues determined that EBP50 is essential for 
neutrophil migration by scaffolding CXCR2 and PLCβ2 (379), and in this study we found that 
EBP50 is important for macrophage activation both in vitro and in vivo. It is becoming 
increasingly clear that EBP50 plays a central role in the activation and function of inflammatory 
cells. 
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Given that EBP50 governs the magnitude of macrophage activation, in particular the pro-
inflammatory genes, we hypothesized that a mouse model with KO myeloid cells would exhibit 
less severe atherosclerosis. Indeed, transplantation of KO bone marrow into Ldlr
-/-
 mice resulted 
in a modest but significant decrease in lesion size in the aorta following a high fat diet. Since KO 
macrophages only exhibit a 50% decrease in inflammatory genes, not a complete ablation, we 
did not expect a total rescue of atherosclerosis in these mice. The environment in these plaques is 
still inflammatory, albeit less so than with WT bone marrow and enough to retard the growth of 
these lesions by 25%. Previous studies deleting components more proximal to NF-κB such as 
IKKβ, which is downstream of EBP50 and can be phosphorylated by kinases other than PKCζ 
(184), demonstrate severely depressed expression of inflammatory genes and thus a further 
decrease in atherosclerosis than what we found here (267, 269). Another report utilized IKKβ-/- 
macrophages and conversely found an increase in severity due to decreased IL-10 and thus a 
defect in inflammation resolution (266). However, EBP50 had no effect on IL-10 expression, 
which may also have contributed to the diminished lesion size in the KO
 
BMT mice. 
Interestingly, KO BMT mice also exhibited increased surface area of lesions along the 
aorta as indicated by en face staining. This would suggest that mice receiving KO bone marrow 
are more sensitive to the initiation of atherosclerosis, although the protrusion of the lesion into 
the lumen (i.e. cross-sectional area) is not as severe as in WT BMT mice. Depending on the 
stability of these KO BMT lesions, having more, smaller lesions could be clinically preferable to 
concentrated, larger plaques. It is also important to remember that the bone marrow contains 
many different cells. We have demonstrated that KO macrophages have decreased cytokine 
secretion and others have shown EBP50 is important for polarization and migration of 
neutrophils (378, 379), but there is also evidence that EBP50 mediates cAMP-dependent T-cell 
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inhibition (418, 419). If KO T-cells are indeed more activated in the context of atherosclerosis, 
this could explain the increased spread of lesions seen in the KO BMT mice. In addition, the 
function of EBP50 in myeloid cells is still relatively unexplored and it is unknown what other 
consequences it could be having (foam cell formation, for example). However, we do know from 
the complete blood count data that EBP50 does not affect hematopoiesis, so the changes we see 
are not due to changes in cell number of any particular myeloid cell population. 
In summary, we have demonstrated a role for EBP50 in the extent of macrophage 
activation. We have also confirmed previous data from VSMC on the involvement of EBP50 in 
the NF-κB pathway. In addition, transplantation of KO bone marrow into Ldlr-/- mice resulted in 
a decrease in lesion size, presumably due to the decreased inflammatory state of KO
 
macrophages. Further assessment of the molecular and cellular composition of these plaques will 
yield further explanation of this phenotype. 
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4.0  GENERAL DISCUSSION 
CVD is the leading cause of death in developing countries, and even with current therapeutics 
the risk of another possibly fatal event is 70-80% (389). This clearly signifies that further 
research is needed into more effective drugs, whether it’s an addition to lipid-lowering drugs for 
atherosclerosis or an alternative to sirolimus- or paclitaxel-coated stents. We have been studying 
a scaffolding protein, EBP50, which may be a new drug target. 
Our lab has been the main trailblazer on the path to determining a niche for EBP50 in the 
vasculature. We started with the observation that EBP50 could inhibit the anti-proliferative 
effects of PTHrP by switching on the Gq-dependent calcium signaling of PTH1R, essentially 
restoring the VSMC to their original benchmark proliferative state. EBP50 can further enhance 
serum-, growth factor-, and cytokine-stimulated VSMC proliferation through the stabilization of 
Skp2 and the subsequent degradation of p21. Additionally, EBP50 is essential for the bridging of 
EGFR to FAK and the initiation of cell migration. Not surprisingly, the indispensable role of 
EBP50 in these critical cellular responses leads to significantly decreased neointima formation in 
response to arterial wire injury in mice lacking this scaffolding protein.  
What is surprising, however, is how a protein with such relatively low expression levels 
in quiescent VSMC can have such a significant influence on the injury response. One answer is 
that injury triggers a 4- to 5-fold increase in EBP50 expression that is only seen in the affected 
  89 
VSMC. This upregulation presumably accounts for the ability of EBP50 to interact with its 
variety of intracellular binding partners and orchestrate these changes.  
 In addition to the aforementioned proliferation and migration, there are many different 
avenues that feed into neointima formation and other vascular diseases including inflammation, 
oxidative stress, lipid metabolism, and the presence of underlying pathologies. The purpose of 
this dissertation was to further characterize the function of EBP50 in the vasculature within an 
inflammatory context and to additionally extend our knowledge of this protein into the realm of 
atherosclerosis. 
4.1 SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
4.1.1 Inflammation Augments EBP50 Expression 
The upregulation of EBP50 has been reported in multiple disease states including hepatocellular 
carcinomas, cholangiopathies, glioblastoma, breast cancer, psoriasis, and vascular injury (311, 
312, 333, 358, 368, 403, 404).  Estrogen is the best-described regulator of EBP50 expression 
(300, 303, 308) and previously our lab discovered a modest PTHrP-induced upregulation of 
EBP50. However, regulation by estrogen and PTHrP is not sufficient to explain the robust effect 
on EBP50 expression seen after wire injury. Murine EBP50 is not responsive to estrogen (313) 
and it is unlikely that the 50% increase induced by PTHrP solely accounts for the 4-5-fold 
upregulation of EBP50 (367). The purpose of this Aim was to uncover other regulators of EBP50 
that could clarify this observation. While I wanted to investigate this in VSMC, I also wanted to 
extend the scope to macrophages. 
  90 
Focusing on inflammatory mediators, LPS and TNFα were both able to increase EBP50 
expression, verifying earlier results by an independent group (386). This was evident at the 
mRNA level and additionally translated into a 2- to 4-fold increase in protein. Furthermore, the 
aortas of LPS-treated mice also displayed increased EBP50 mRNA, although I did not have 
enough mice to reach significance. This increase was dependent upon NF-κB, a ubiquitous 
inflammatory transcription factor, as demonstrated by the lack of effect when simultaneously 
treated with an IKK inhibitor or a nondegradable IκBα construct. Simple overexpression of the 
p65 subunit of NF-κB was enough to mimic this effect without further stimulus. These results 
were manifested in both VSMC and macrophages (primary and clonal).  
This considerable increase in EBP50 after treatment with inflammatory mediators takes 
us one step closer to explaining the upregulation we see in the neointima. This in vivo effect is 
probably the result of multiple factors including PTHrP and TNFα, and possibly others. LPS is 
present in very small amounts in circulation (those with bacterial infections have higher 
concentrations) and, depending on the status of the patient, may or may not have a physiological 
hand in EBP50’s upregulation. Although I have not tested it, it is more likely that IL-1β takes the 
place of LPS in this pathway since they share very similar signaling cascades culminating in NF-
κB activation. I have conducted very limited testing to determine if growth factors such as EGF 
and PDGF have a similar effect on EBP50 expression given that they are both able to stimulate 
NF-κB. So far I have not seen any effect of these stimuli on EBP50. However, these experiments 
are very preliminary and require further analysis to determine if other mediators with NF-κB 
implications are effective. If our pilot data holds and these growth factors are ineffective, it 
would be interesting to delineate the molecular determinants of why one stimulus is effective vs. 
another. 
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I have convincingly shown that NF-κB is necessary for EBP50 upregulation, yet I cannot 
conclusively say that NF-κB directly binds the promoter. There are multiple NF-κB consensus 
sites on the Slc9a3r1 (EBP50) promoter, two of which are a perfect match, so the possibility 
does exist. However, I do not know how much “wobble” is allowed for those sites which do not 
100% match the consensus sequence. The increase in EBP50 is seen relatively late in the 
activation of NF-κB (8-16 hours), and it is possible that this is a secondary effect of NF-κB 
signaling. Determining the binding site for NF-κB on the Slc9a3r1 promoter would be one future 
direction. To accomplish this, the appropriate cells could be transfected with a luciferase 
construct under the control of the Slc9a3r1 promoter and treated with LPS or TNFα to observe 
the change in transcription. Serial truncations can then be made to determine the responsible 
portion of the promoter. Electrophoretic mobility shift assays and chromatin 
immunoprecipitations could verify that this aforementioned promoter sequence binds to NF-κB.  
 Finally, it would be advantageous to determine the kinetics of EBP50 upregulation for the 
application of therapeutics in the developing neointima. We have observed that EBP50 is still 
increased at the peak of neointimal growth two weeks after injury, but it is unknown when this 
event begins. Judging by our data on cytokine influence, one would hypothesize that this 
happens a few days after injury when the macrophages arrive. Since we have had trouble with 
EBP50 immunofluorescence in the past, a more clear-cut and quantitative method would be to 
use pinpoint slide RNA isolation to assess EBP50 expression in the neointima versus the media. 
4.1.2 EBP50 is Integrated into the NF-κB Signaling Pathway 
EBP50 is a positive regulator of proliferation and migration, but I wanted to explore other 
possible functions for the scaffolding protein. The purpose of this Aim was to determine the 
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involvement of EBP50 in NF-κB activation. Indeed, EBP50 promotes NF-κB signaling. This is 
consistent with data from the literature showing a dependency on EBP50 for NF-κB binding to 
DNA in bronchial epithelial cells (391).  However, my work extended these findings further up 
the signaling pathway. EBP50-null VSMC displayed decreased IKK, IκBα, and p65 
phosphorylation, IκBα degradation, and p65 nuclear translocation. Both PDZ domains of EBP50 
and the ability to bind the cytoskeleton are essential for these effects. Additionally, these VSMC 
exhibited decreased adhesion molecules (ICAM-1, VCAM-1). The effect of EBP50 on NF-κB 
activity and thus gene expression is not receptor-specific since it was observed with both LPS 
and TNFα. However, the lack of EBP50 does not exert a global effect on signaling as activation 
of p38 and c-Jun was not affected in KO VSMC. These phenomena of decreased adhesion 
molecules without EBP50 were also observed in an in vivo model of LPS-injected mice. 
Furthermore, I demonstrated that macrophage infiltration in our arterial injury model was 
decreased at the one-week time-point in KO mice. 
It is interesting that EBP50 does not affect all NF-κB genes equally. Many cytokines and 
adhesion molecules are decreased in KO conditions, but the stimulation of MCP-1, IL-10, and 
IL-6 is unaffected by the absence of EBP50. While the reason for this has not been 
experimentally proven, it is likely that there are factors pertaining to both EBP50 and the specific 
promoter region which should be taken into consideration. Even though EBP50 has no effect on 
p38 or c-Jun pathways, the scaffolding protein could affect the activation of other transcription 
factors. EBP50 may positively regulate a pathway that feeds into the transcription of TNFα and 
IL-1β, for example, but not IL-6 or IL-10. In addition, there may be variability in NF-κB 
dependence among the different promoters.  
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Mechanistically, EBP50 interacted with PKCζ, an upstream activator of the IKK 
complex. This interaction is dependent upon the C-terminal PDZ motif of PKCζ (E-E-S-V), and 
mutation of this motif also abrogated NF-κB activation. Interestingly, overexpression of PKCζ 
was unable to rescue the KO phenotype, but the addition of a constitutively membrane-bound 
myristoylated PKCζ surprisingly restored NF-κB signaling. From this, I hypothesized that 
EBP50 is important for PKCζ membrane translocation. PKCζ did not accumulate at the 
membrane after stimulation in CHO cells, which do not express EBP50, but started to gradually 
increase after addition of EBP50. The magnitude of this effect is consistent with that observed in 
response to dopamine in OK cells (405). Together, these experiments established that EBP50 
promotes NF-κB activation through the formation of an EBP50-PKCζ complex at the cell 
membrane. 
The interaction between EBP50 and PKCζ was not only dependent on PDZ features but 
on the addition of a stimulus. During basal conditions, there was no evidence of an association, 
yet a few minutes of TNFα treatment yielded a complex containing EBP50 and PKCζ. What are 
the molecular determinants that permit this interaction after stimulation but not before? The C-
terminal PDZ motif of PKCζ, E-E-S-V, contains a serine and phosphorylation of PDZ motifs 
have been shown to enhance binding (420). However, there are no reports of additional 
phosphorylation events within PKCζ aside from the T410 priming site and autophosphorylation 
at T560. Additionally, phosphorylation of the PDZ motif has more often demonstrated to inhibit 
binding to its respective PDZ domain (421). A more likely scenario is that EBP50 is 
phosphorylated in response to stimuli in a manner that enhances interactions. Phosphorylation of 
EBP50 has been previously shown to increase interactions, theoretically from conformational 
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changes (318). It is possible that EBP50 is phosphorylated in response to TNFα and other 
mediators, leading to its association with PKCζ. 
Other future experiments pertaining to this interaction would be to 1) demonstrate that 
EBP50 and PKCζ do directly bind through GST pull-downs or blot overlays, and 2) determine 
which PDZ domain is necessary for this interaction using PDZ mutants of EBP50. Since 
mutation of the PKCζ PDZ motif completely abrogates its association with EBP50, the two 
proteins would be expected to directly bind. 
In contrast to the function of PKCζ in fibroblasts yet consistent with analysis in the lung 
(246), I have added VSMC to the list of cell types in which PKCζ acts on IKK to activate NF-
κB. I also did not check the effect of EBP50 on S311 phosphorylation on p65, a residue 
specifically phosphorylated by PKCζ (256). This should be explored in the future in order to 
make this a more complete body of work. 
I chose to focus on VSMC and macrophages in this dissertation since we had previous 
data on EBP50 in VSMC and because macrophages also play a major role in restenosis. The 
endothelium is not as important in neointima formation as the majority of cells are removed. 
Preliminary data in the lab suggests that EBP50 has no effect on the proliferation or migration of 
endothelial cells, functions that could affect re-endothelialization after denudation. However, 
endothelium dysfunction is critical for macrophage infiltration in atherosclerosis and sepsis. I 
noticed that ICAM-1 and VCAM-1 expression in the endothelium in vivo is decreased after LPS 
injections in KO mice. It is possible that NF-κB signaling is also deficient in the null endothelial 
cells, adding to the repertoire of tissues in which EBP50 modulates inflammation.  
These studies have all been performed in cells of mouse origin, and new binding partners 
for EBP50 are likely to emerge if human cells are investigated. While mouse TLR4 has a C-
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terminus of A-T-W-T, the human homolog terminates in A-T-S-I. The difference of the final 
amino acid means that the human TLR4 ends in a hydrophobic residue and thus fits the 
consensus motif to bind EBP50. The direct interaction of these two proteins could provide a 
whole new level of TLR4 and NF-κB regulation in addition from PKCζ translocation. Modifying 
membrane TLR4 quantities could not only affect NF-κB activation but could also influence the 
magnitude and duration of endocytosis-mediated MyD88-independent signaling of TLR4. 
It is intriguing that EBP50 and NF-κB can mutually upregulate each other’s activity 
and/or expression, similar to the cycle in which cytokines such as IL-1β and TNFα are involved. 
EBP50 promotes NF-κB activation, which in turn increases EBP50 expression.  This suggests 
that EBP50 helps keep NF-κB “turned on” for more rounds of activation in order to propagate 
inflammation. Since more receptors are being activated in the face of increased stimulation (as 
from the NF-κB-targeted TNFα or IL-1β), additional EBP50 may be needed to shuttle PKCζ to 
these membrane complexes. EBP50 is necessary but not sufficient for NF-κB activation, and I do 
not think the increased presence of EBP50 in the cell would interfere with the termination 
mechanisms of NF-κB. This is a scaffolding protein, not a kinase, and it does not possess 
constitutive activity in the absence of stimuli that could override inhibitory processes. I have 
completed the necessary EBP50 knockdown and null experiments, but have not performed 
overexpression studies. These would help clarify the purpose of EBP50 upregulation in the face 
of NF-κB activation. 
4.1.3 EBP50 Increases Macrophage Activation and Atherosclerosis 
Since I found EBP50 to govern the inflammatory response of VSMC, the first goal of this Aim 
was to examine the role of EBP50 in macrophage activation. EBP50 is starting to emerge as an 
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important modulator of leukocyte function. Through its scaffolding abilities, EBP50 is a positive 
regulator of neutrophil polarization (378) and migration (379) as well as the bactericidal activity 
of macrophages (386). I have added to that growing body of knowledge by investigating the 
effect of EBP50 on macrophage activation. Macrophages displayed diminished cytokine 
production (IL-1β, TNFα) and NF-κB activation without EBP50, and this was also reflected with 
in vivo LPS treatments. Interestingly, the absence of EBP50 did not alter IL-10 expression, 
suggesting that the scales could be tipped in favor of anti-inflammatory events and lead to a more 
efficient resolution of inflammation. 
One limitation of this study is that I was not able to test the involvement of the EBP50-
PKCζ complex on NF-κB activation in macrophages. I did establish a deficiency in NF-κB 
activation in macrophages treated with EBP50 siRNA similar to what I previously saw in KO 
VSMC. However, it would be interesting to see if the same mechanism I discovered in VSMC 
with PKCζ translates to macrophages as well. In addition, PKCζ is a main regulator of the M2 
phenotype in response to IL-4 stimulation (422). EBP50 has not previously been implicated in 
the IL-4 pathway. I hypothesize that there would also be decreases in Jak1 and Stat6 
(components of the IL-4 pathway) activation in KO cells, as well as IL-4 target genes. In 
addition, EBP50 and PKCζ should also experience a stimulus (IL-4)-dependent interaction, 
similar to what I’ve seen with TNFα treatment. 
 We have shown in previous studies and in this thesis that EBP50 is a positive regulator of 
acute inflammation resulting from surgical injury and LPS insult. Next, I wanted to investigate 
the role of EBP50 in atherosclerosis, a chronic form of inflammation. Given the interesting data I 
collected on EBP50 in macrophages, I wanted to focus on the contribution of 
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leukocyte/lymphocyte EBP50 in atherosclerosis. While there is much analysis left to do, KO 
BMT mice had significant reductions in lesion size. 
Evaluation of the molecular and cellular composition of these plaques mainly includes 
macrophage, VSMC, collagen, and apoptotic content, as well as adhesion molecule expression. 
In addition, the ability of KO
 
macrophages to form foam cells must be assessed. I hypothesize 
that the decreased M1 activation of the KO bone marrow cells is the reason for the moderate 
decrease in atherosclerosis. With that in mind, I would expect to see plaques with less 
macrophage infiltration and adhesion molecule expression. I do not anticipate changes in 
apoptotic areas or foam cell formation. Evaluation of the plaque composition may also shed 
insight into the increased spread of lesions in the KO BMT as demonstrated by the en face 
staining of the aorta. Other analyses include EBP50 expression in the plaque. Since we’ve 
previously shown that EBP50 expression is increased in the neointima of injured vessels (367), it 
would be interesting to see if this pattern continues in atherosclerosis. Both the neointima and 
atherosclerotic lesions are inflammatory environments so I would expect EBP50 to be similarly 
increased. 
Since EBP50 also had an effect on the VSMC response, a double knockout 
(Slc9a3r1/Ldlr) will probably decrease atherosclerosis even further. KO macrophages secrete 
lower amounts of cytokines, but I would predict that the inability of KO VSMC to fully respond 
to a stimulus (i.e. adhesion molecule expression) would at least have an additive effect on the 
decreased lesion size seen here. I showed in Chapter 2 that macrophage infiltration into the 
neointima of KO mice is diminished, and I would expect the same result here in a double 
knockout background. It may be seen as disadvantageous to potentially abolish the formation of 
a fibrous cap due to the decreased proliferation and migration of KO VSMC, but if the plaque is 
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already less inflammatory due to reduced macrophage infiltration (and thus a smaller or 
nonexistent necrotic core) a fibrous cap would not be necessary. In fact, without a necrotic core 
to protect, a fibrous cap could just be an additional burden of the plaque protruding into the 
lumen and possibly impeding blood flow. 
Similar to the bone marrow transplant methodology I conducted in this thesis, where I 
evaluated the contribution of KO macrophages to atherosclerosis, WT bone marrow could be 
transplanted into the double knockout model. This would conversely demonstrate the relative 
influence of KO VSMC and endothelium on the progression of atherosclerosis. Since EBP50 had 
a greater effect on VSMC than in macrophages, as assayed by relative decreases in gene 
expression, I would hypothesize that this model would display a greater decrease in lesion size 
than the KO BMT model I used in this dissertation. I would still expect the double knockout to 
have a greater rescue of atherosclerosis severity. 
4.2 CONCLUDING REMARKS 
The goal of this study was to further characterize the role of EBP50 in the vasculature, 
particularly in regards to inflammatory conditions. I have investigated the effect of EBP50 on the 
initiation and progression of inflammation, as well as the converse consequences of 
inflammation on EBP50. In doing so, I have demonstrated that: 
 NF-κB is the main regulator of EBP50 expression in response to inflammatory stimuli.  
 EBP50 promotes NF-κB activation in macrophages and VSMC, culminating in the 
expression of cytokines and adhesion molecules. In VSMC, this novel mechanism is 
driven by the recruitment of PKCζ to the membrane. 
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 EBP50-null myeloid cells in an Ldlr-/- background result in a significant decrease in 
atherosclerosis. 
Inflammation is abundant in many other diseases including, but not limited to, cancer, 
asthma, rheumatoid arthritis, and sepsis. It is likely that the effect of EBP50 on inflammation and 
thus the findings of this thesis can extend to other disorders besides CVD. 
In conclusion, this dissertation has demonstrated that EBP50 is a central mediator of 
macrophage activation and the response of VSMC to inflammation, culminating in 
atherosclerosis. 
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